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A B S T R A C T
Background
Despite efforts to preserve the neurovascular bundles with nerve-sparing surgery, erectile dysfunction remains common following radical
prostatectomy. Postoperative penile rehabilitation seeks to restore erectile function but results have been conflicting.
Objectives
To evaluate the effects of penile rehabilitation strategies in restoring erectile function following radical prostatectomy for prostate cancer.
Search methods
Weperformed a comprehensive search of multiple databases (CENTRAL,MEDLINE, Embase), the Cochrane Library,Web of Science,
clinical trial registries (ClinicalTrials.gov, International Clinical Trials Registry Platform) and a grey literature repository (Grey Literature
Report) from their inception through to 3 January 2018. We also searched the reference lists of other relevant publications and abstract
proceedings. We applied no language restrictions.
Selection criteria
We included randomised or quasi-randomised trials with a parallel or cross-over design.
Data collection and analysis
We used standard Cochrane methodological procedures. Two review authors independently screened the literature, extracted data,
assessed risk of bias and rated quality of evidence according to GRADE on a per-outcome basis. Primary outcomes were self-reported
potency, erectile function measured by validated questionnaires (with potency defined as an International Index of Erectile Function
(IIEF-EF) score of 19 or greater and or an IIEF-5 of score of 17 or greater) and serious adverse events. For all quality of life assessments
on a continuous scale, higher values indicated better quality of life.
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Main results
We included eight randomised controlled trials with 1699 participants across three comparisons. This abstract focuses on the primary
outcomes of this review only.
Scheduled phosphodiesterase type 5 inhibitors (PDE5I) versus placebo or no treatment
Scheduled PDE5I may have little or no effect on short-term (up to 12 months) self-reported potency (risk ratio (RR) 1.13, 95%
confidence interval (CI) 0.91 to1.41; very low quality evidence), which corresponds to 47 more men with self-reported potency per
1000 (95% CI 33 fewer to 149 more) and short-term erectile function as assessed by a validated instrument (RR 1.11, 95% CI 0.80
to 1.55; very low quality evidence), which corresponds to 28 more men per 1000 (95% CI 50 fewer to 138 more), but we are very
uncertain of both of these findings. Scheduled PDE5I may result in fewer serious adverse events compared to placebo (RR 0.32, 95%
CI 0.11 to 0.94; low quality evidence), though this does not appear biologically plausible and may represent a chance finding. We are
also very uncertain of this finding. We found no long-term (longer than 12 months) data for any of the three primary outcomes.
Scheduled PDE5I versus on-demand PDE5I
Daily PDE5I appears to result in little to no difference in both short-term and long-term (greater than 12 months) self-reported potency
(short term: RR 0.97, 95%CI 0.62 to 1.53; long term: RR 1.00, 95%CI 0.60 to 1.67; both very low quality evidence); this corresponds
to nine fewer men with self-reported short-term potency per 1000 (95% CI 119 fewer to 166 more) and zero fewer men with self-
reported long-term potency per 1000 (95% CI 153 fewer to 257 more). We are very uncertain of these findings. Daily PDE5I appears
to result in little to no difference in short-term and long-term erectile function (short term: RR 1.00, 95% CI 0.65 to 1.55; long term;
RR 0.74, 95% CI 0.48 to 1.14; both very-low quality evidence), which corresponds to zero men with short-term erectile dysfunction
per 1000 (95% CI 80 fewer to 125 more) and 119 fewer men with long-term erectile dysfunction per 1000 (95% CI 239 fewer to 64
more). We are very uncertain of these findings. Scheduled PDE5I may result in little or no effects on short-term adverse events (RR
0.69 95% CI 0.12 to 4.04; very low quality evidence), which corresponds to seven fewer men with short-term serious adverse events
(95% CI 18 fewer to 64 more), but we are very uncertain of these findings. We found no long-term data for serious adverse events.
Scheduled PDE5I versus scheduled intraurethral prostaglandin E1
At short-term follow-up, daily PDE5I may result in little or no effect on self-reported potency (RR 1.10, 95% CI 0.79, to 1.52; very
low quality evidence), which corresponds to 46 more men per 1000 (95% CI 97 fewer to 241 more). Daily PDE5I may result in a
small improvement of erectile function (RR 1.64, 95% CI 0.84 to 3.20; very low quality evidence), which corresponds to 92 more
men per 1000 (95% CI 23 fewer to 318 more) but we are very uncertain of both these findings. We found no long-term (longer than
12 months) data for any of the three primary outcomes.
We found no evidence for any other comparisons and were unable to perform any of the preplanned subgroup analyses based on nerve-
sparing approach, age or baseline erectile function.
Authors’ conclusions
Based on mostly very-low and some low-quality evidence, penile rehabilitation strategies consisting of scheduled PDE5I use following
radical prostatectomy may not promote self-reported potency and erectile function any more than on demand use.
P L A I N L A N G U A G E S U M M A R Y
Penile rehabilitation for post prostatectomy erectile dysfunction
Review question
How well do treatments work to restore men’s ability to have erections after surgery for prostate cancer?
Background
Many men have problems with erections after having their prostate removed for prostate cancer. Studies suggest that taking certain
medicines or using devices to help with erection may help men’s erections recover faster and better when used on a regular, scheduled
basis (like daily or twice a week) rather than as needed. However, it is unclear how well these treatments actually work.
Study characteristics
2Penile rehabilitation for postprostatectomy erectile dysfunction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We included eight randomised studies (clinical studies where people are randomly put into one of two or more treatment groups) with
1699 participants. Five trials compared the scheduled use of phosphodiesterase inhibitors (a type of medicine) to either no treatment
or a placebo (a pretend drug with no effect). Two studies compared the use of phosphodiesterase inhibitors either as a daily prescription
or as needed. One study compared the daily use of either a phosphodiesterase inhibitor or a medicine called prostaglandin E1 that is
placed into the tip of the penis like a suppository. The main outcomes of this review that we felt were most important to men were
how good they thought their erections were (self-reported potency), how good their erections were based on a specialised erection
questionnaire (quality of erections) and any whether there were any major unwanted side effects.
Key results
We found that the men who used these medicines on a scheduled basis may have had similar self-reported erections and quality of
erections (based on questionnaires they filled out) as men who took no medication regularly or use it as needed. They also had similar
rates of serious unwanted side effects and similar rates of stopping the drug before the end of the treatment duration. However, we are
very uncertain of these findings. We were unable to research whether these results would be different in different groups of men based
on whether the surgeon tried to preserve the nerves that help with erections or not, based on men’s age and how good their erections
were beforehand because we found no studies.
Reliability of evidence
The quality of evidence was very low for most main outcomes. That means we are very uncertain of the results of this review. Further
research will likely change these findings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Scheduled PDE5I compared to on demand placebo or no treatment for post-prostatectomy erectile dysfunction (short- term)
Patient or population: post-prostatectomy erect ile dysfunct ion (short-term)
Setting: outpat ient clinic
Intervention: scheduled PDE5I
Comparison: on demand placebo or no treatment
Outcomes of participants
(studies)
Follow up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI)
Risk with on demand placebo
or no treatment
Risk difference with sched-
uled PDE5I
Self- reported potency
assessed with: Sexual En-
counter Prof ile diary ques-
t ion 3 or self report
follow up: range 24 weeks
to 46 weeks
628
(4 RCTs)
⊕©©©
VERY LOW 123
RR 1.13
(0.91 to 1.41)
Study populat ion
364 per 1,000 47 more per 1,000
(33 fewer to 149 more)
Erectile function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main
follow up: range 24 weeks
to 48 weeks
757
(5 RCTs)
⊕©©©
VERY LOW 123
RR 1.11
(0.80 to 1.55)
Study populat ion
250 per 1,000 28 more per 1,000
(50 fewer to 138 more)
Serious adverse events
f ollow up: range 24 weeks
to 48 weeks
443
(3 RCTs)
⊕⊕©©
LOW 14
RR 0.32
(0.11 to 0.94)
Study populat ion
64 per 1,000 44 fewer per 1,000
(57 fewer to 4 fewer)
Sexual quality of life - not
reported
- - - - -
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Treatment discontinuation
f ollow up: range 24 weeks
to 48 weeks
443
(3 RCTs)
⊕©©©
VERY LOW 13
RR 0.98
(0.72 to 1.34)
Study populat ion
246 per 1,000 5 fewer per 1,000
(69 fewer to 84 more)
International Index of Erec-
tile Function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main
Scale f rom: 1 (worst: severe
ED) to 30 (best: no ED)
follow up: mean 48 weeks
356
(2 RCTs)
⊕⊕©©
LOW 145
- The mean internat ional Index
of Erect ile Funct ion ranged
f rom 8.8 to 12.4
MD 2.09 higher
(1.85 lower to 6.03 higher)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
2 Downgraded by one level for indirectness: dif f erence in outcome measure.
3 Downgraded by two levels for imprecision: wide conf idence interval crosses assumed threshold of clinically important
dif f erence.
4 Downgraded by one level for imprecision: conf idence interval crosses assumed threshold of clinically important dif f erence.
5 Not downgraded for inconsistency despite substant ial heterogeneity given that likely not clinically meaningful.
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B A C K G R O U N D
Prostate cancer is the most common non-skin cancer in men. In
2014 in the UK alone, there were 46,700 new cases of prostate
cancer diagnosed accounting for about 13% of all new cancer di-
agnoses. Prostate cancer in 2016 resulted in about 11,500 deaths
in the UK making it the second most common cancer related
cause of death inmen (Cancer ResearchUK). In theUSA, prostate
cancer accounted for 172,258 new cancer diagnoses and caused
28,343 deaths in 2014 (U.S. Cancer Statistics Working Group).
For organ-confined prostate cancer (pT2), treatment options with
curative intent include mainly radical prostatectomy (RP) and
radiotherapy. RP can be undertaken as an open procedure typi-
cally through a retropubic approach (RRP), laparoscopic (LRP)
or robotic-assisted (RARP). Radiotherapeutic options for prostate
cancer include external beam radiotherapy (EBRT) typically de-
livered as 2 Gy fractions over seven weeks to a total of 70 Gy with
or without concomitant hormone treatment. Other therapeutic
options that involve radiotherapy include intensity-modulated ra-
diotherapy and brachytherapy. Active surveillance of prostate can-
cer also falls into the category of treatments with curative intent.
This treatment approach consists of an active decision not to treat
the prostate cancer at the time of diagnosis but rather to monitor
the man closely to enable the proper timing of curative treatment,
taking into account the man’s life expectancy. It is advocated by
EuropeanHeidenreich 2014 and American Sanda 2017 urological
guidelines in men with low-risk organ-confined prostate cancer.
RP has the potential to completely remove the tumour and re-
mains a preferred and effective treatment modality utilised as a
first option in approximately 33% of prostate cancer cases with
organ-confined disease and in 52% of cases in men aged over 62
years of age (Lalong-Muh 2012; American Cancer Society 2014).
In 2010 in the US alone, there were 11,290 prostatectomies, two-
thirds of which were RARP. These figures compared to the data
from 2004, when there were 6188 prostatectomies, of which only
8% were RARP, suggests that RP rates have risen exponentially
since the introduction of RARP (Lowrance 2012).
The common adverse effects of RP include erectile dysfunction
(ED) and urinary incontinence. Many factors influence the inci-
dence and severity of postoperative ED, including man’s age, tu-
mour stage, preoperative potency, length of surgical intervention
and experience of the surgeon (Wang 2014). Despite meticulous
dissection in an attempt to preserve the neurovascular bundleswith
nerve-sparing surgery, ED remains common. Even with nerve-
sparing surgery, there is a period of neuropraxia during which the
man has no spontaneous erections. This can lead to penile hy-
poxia and long-lasting damage to the erectile tissue (Burnett 2005;
Raina 2010). The length of time that neuropraxia and consequent
ED will last is difficult to predict, with some studies suggesting
manymen require more than two years to recover erectile function
satisfactorily (Rabbani 2010).
The introduction of the robot-assisted technology has refined
nerve-sparing procedures mainly through three-dimensional mag-
nification and movement calibration that could result in reduced
postprostatectomy ED rates. One systematic review evaluated the
prevalence and the potential risk factors of ED after RARP. Their
findings suggested that the prevalence of ED ranged from 54%
to 90% at 12 months and 63% to 94% at 24 months (Ficarra
2012). RARP had a significant advantage over RRP with an ED
prevalence of 24.2% with RARP versus 47.8% with RRP at 12
months (Ficarra 2012). However, despite these technological ad-
vances, ED is still significant in this patient population. This has
led to the development of penile rehabilitation programmes that
aim to promote male sexual function before and after any insult
to the penile erectile physiological axis. Penile rehabilitation has
now become an integral part of patient management after RP and
most urologists advocate that this should be commenced as soon
as possible following surgery.
Description of the condition
Male sexual dysfunction related to prostate cancer treatment can
be divided into three broad categories: ED and changes in penile
size; ejaculatory and orgasmic dysfunction; and psychosexual im-
pairmentwith changes in sexual desire, intimacy andmental health
(Chung 2013). ED is defined as the inability of a man to achieve
and maintain an erection of sufficient strength for satisfactory sex-
ual activity (NIH Consensus Conference 1993). It’s incidence re-
ported in the literature after RP varies dramatically from 20% to
90% (Fowler 1993; Rabbani 2000; Stanford 2000; Kundu 2004;
Rozet 2005; Penson 2008; Alemozaffar 2011). The discrepancy
in the reported rates of erectile function after RP is due to many
factors. These include variations in study population demograph-
ics, methods of data acquisition, variability in questionnaire use,
duration of postoperative follow-up, variations in baseline erectile
function status, inconsistency in defining adequate erectile func-
tion, surgical technique, and the definition of quality and consis-
tency of erection (Mulhall 2009). ED can have a major impact
on the man’s self-esteem, quality of life (QoL), confidence and
life satisfaction, causing depression in certain cases (Kubin 2003).
Quantifying accurately the prevalence of ED after RP is of utmost
importance in evaluating the burden of this treatment-related ad-
verse effect, in order to set appropriate expectations and facilitate
medical decision making. One analysis identified 24 studies that
originated from major cancer centres and reported ED recovery
outcomes after RP, in large participant cohorts (Mulhall 2009). In
these studies, the mean overall rates of erectile function recovery
were 48% (standard deviation (SD) 25%; range 12% to 96%).
When nerve sparing was accounted for, as it was in 14 (58%) of
the 24 articles reviewed, mean erectile function recovery rates were
50% (SD 24%) for bilateral and 34% (SD 16%) for unilateral
nerve-sparing surgery.
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The starting point for analysing data on penile rehabilitation is
objectively defining ED and reaching a consensus as to the defi-
nition of return to potency following RARP. Unfortunately, there
remains significant heterogeneity in the literature in terms of defi-
nitions of ED after RP, and a significant number of studies do not
clearly state their definitions of ED or return to sexual function.
Scoring systems such as SexualHealth Inventory ForMen (SHIM)
scores, International Index of Erectile Function (IIEF-5), sexual
questionnaires, and patient and partner reporting are all prone
to inaccuracies. Therefore, evaluating return of potency following
RARP in the absence of a consensus definition was a challenge
for this review. For the purposes of this study as outlined in more
detail in the ’methodology’ section, we included men with erectile
function sufficient for intercourse. According to the IIEF-5 and
IIEF questionnaires, we defined ’sufficient for intercourse’ as men
with mild (IIEF-5 greater than 17) or no (IIEF greater than 19)
ED. Therefore, we defined return to sexual function as return to
baseline IIEF-5/IIEF scores.
Description of the intervention
Penile rehabilitation following RP revolves around the use of med-
ications (alone or in combination) or devices to preserve erectile
tissue health andmaximise erectile function recovery or both med-
ications and devices (Mulhall 2010). The treatment options in-
clude: phosphodiesterase-5 inhibitors (PDE5I) (sildenafil citrate;
tadalafil; vardenafil) scheduled or daily dosing; alprostadil prepa-
rations (prostaglandin E1, such as Viridal Duo or Caverject as in-
jectables, or Medicated Urethral System for Erections (MUSE) as
urethral pellets), and vacuum erection or vacuum constriction de-
vices (VED/VCD) (Steggall 2011; Weyne 2015). These interven-
tions have been used singly or in combination, either presurgery
or following successful trial without catheter following surgery,
and at different strengths, dosing frequencies and combinations,
to attempt to identify the most suitable option to prevent or limit
neuropraxia, recover erections and restore sexual activity.
How the intervention might work
The main pathophysiological mechanism which underlies the de-
velopment of ED after RP is damage to the cavernosal nerves and
vascular injury. Damage to these nerves occurs either due to their
complete transection during non-nerve-sparing procedures or due
to neuropraxia which commonly occurs during nerve-sparing RP.
Neuropraxia is defined by the transient block of nerve transmis-
sion despite an anatomically intact nerve, caused in this case by
direct trauma, stretching, heating due to electrocautery, ischaemia
and local inflammation (Fode 2013). Vascular injury primarily in-
volves damage to the accessory pudendal arteries. This, together
with the direct effect of loss of cavernosal nerve function results in
a reduction in the oxygenation of penile tissues due to structural
changes in vascular smooth muscle and endothelium. This ulti-
mately causes loss of smooth muscle due to apoptosis (Kendirci
2006), impaired veno-occlusive function, collagen accumulation
and penile fibrosis (Hatzimouratidis 2009; Kacker 2013). Collec-
tively these physiological changes result in ED and penile short-
ening.
Surgical intervention is known to induce hypoxia in a time-de-
pendent manner, such that the potential for recovery of erectile
function decreases with time. The goal of early intervention with
penile rehabilitation strategies is to improve the oxygenation of
cavernosal tissue during the period of neuropraxia, to prevent un-
inhibited deterioration of penile tissues and tominimise (if not ab-
rogate) the adverse structural and physiological changes that occur
in the penis following RP. Penile rehabilitation also ensures that
the man is well-placed to regain presurgery erectile function and
not remain dependent on erectile aids following surgery (Burnett
2013; Segal 2013). Oral PDE5I by virtue of their ease of use, are
often considered as the mainstay of ED management. They are
generally well-tolerated, have proved to be relatively safe and are
the preferred treatment after RP in some centres. Nevertheless,
there are a number of men with postsurgery ED, who do not re-
spond to PDE5I, or who become less responsive and less satisfied
as treatment progresses. In some men, PDE5I are contraindicated
by virtue of the use of nitrate medication and the risk of conse-
quent hypotension. Apart from the oral PDE5I, the other options
for management of postprostatectomy ED (including MUSE and
intracavernosal injections (ICIs)) are invasive, uncomfortable, un-
appealing and sometimes ineffective for some men. While PDE5I
may be appealing as they appear ’easy’ to use, there are limited data
examining whether PDE5I aid penile rehabilitation in a time-de-
pendent manner, which is critical as men often prefer to manage
their incontinence before their erections, and if treatment is not
introduced early, there is a risk of penile atrophy that will make
the recovery of erections more problematic.
Why it is important to do this review
ED is a common adverse event of RP and it significantly affects
QoL. The aforementioned new insights into the pathophysiol-
ogy of post-RP ED have led to the development of a multitude
of different penile rehabilitation strategies which aim to improve
the oxygenation of penile tissues during the period of neuropraxia
that inevitably follows RP in the hope to reduce the rate of post-
prostatectomy ED and restore sexual activity without the use of
erectogenic aids. Several randomised controlled trials (RCTs) have
been published which address the question of whether these treat-
ment modalities (alone/in combination and at different dosages or
dosing schedules) are of any benefit in reducing the incidence of
ED after RP and hasten the return to unassisted sexual function.
Currently there is still controversy regarding the effectiveness of
rehabilitation programmes. The purpose of this review is to sys-
tematically evaluate these treatment options and combinations to
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identify whether any of these can recover erections and restore sex-
ual activity in addition to evaluating other important clinical out-
comes such as adverse events, treatment acceptability by patients,
treatment discontinuation rates and QoL. Our further aim is to
compare, where evidence exists, different treatment modalities be-
tween them and determine which, if any, of these treatments may
be most beneficial to restoring unassisted erectile function in men
with postprostatectomy ED.
O B J E C T I V E S
To evaluate the effects of penile rehabilitation strategies in restor-
ing erectile function following radical prostatectomy for prostate
cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs with a parallel or cross-over design, and quasi-
randomised controlled trials (where participants were allocated to
different arms of the trial using a method of allocation that was
not truly random). Due to the nature of the review question, we
did not consider cluster-RCTs.
Types of participants
Men (aged 18 years or over), who received radical surgical inter-
vention for clinically organ-confined prostate cancer (cT1 or T2,
N0 and M0) irrespective of disease risk status. We also considered
men with T3 disease who were treated by RP alone and received
no other form of adjuvant or neoadjuvant therapy. We consid-
ered all surgical approaches of RP such as RRP, radical perineal
prostatectomy, laparoscopic prostatectomy and robot-assisted la-
paroscopic prostatectomy, irrespective of the nerve-sparing status.
We excluded men who had received RP as a salvage procedure fol-
lowing failed primary therapy with another treatment modality.
We also excluded men who were administered androgen depriva-
tion therapy (ADT) or salvage RT due to biochemical recurrence
following RP. We only included men who had erectile function
sufficient for intercourse prior to surgery, as documented by an
IIEF score. We defined these men as those who had IIEF or IIEF-
5 scores within the mild or no ED range (mild: IIEF 19 or greater;
none: IIEF-5 17 or greater). We chose these baseline IIEF scores
as they included men with mild and no erectile function which we
consider as having erectile function sufficient for intercourse. Men
also needed to have a heterosexual partner and be sexually active.
We focused on men in heterosexual relationships since it has been
reported that anal intercourse requires 33% greater penile rigidity
(Gebert 2014).
Types of interventions
To allow a fair and accurate comparison of efficacy of these agents
in improving the recovery of erectile function, participants within
experimental or placebo groups needed to, at the time of outcome
assessment, be receiving no treatment for erectile function or be
receiving the same treatment (e.g. the same type and dosage of
PDE5I). We excluded any RCTs that did not provide this fair
comparison. We included studies of psychological interventions
only if these were offered in combination with pharmacological
interventions, or were received by participants in both the inter-
vention and control groups.
We planned to investigate the following experimental versus com-
parison interventions.
Experimental interventions
• PDE5I scheduled (e.g. daily or twice per week).
• Prostaglandin E1 (alprostadil) scheduled administered as
ICIs.
• Prostaglandin E1 (alprostadil) scheduled administered
intraurethrally (MUSE and Vitaros (alprostadil topical cream)).
• Scheduled use of VEDs or VCDs
• Scheduled use of combination treatments (e.g. PDE5I and
VEDs).
Comparator interventions
• Placebo or no intervention/observation.
• On demand intervention
• Different types of active interventions listed under the
experimental interventions above but administered on demand
Comparisons
Experimental intervention versus comparator intervention.
Types of outcome measures
We considered trials with a minimum follow-up of six weeks.
Primary outcomes
• Self-reported potency.
• Erectile function.
• Serious adverse events.
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Secondary outcomes
• Sexual QoL.
• Treatment discontinuation.
• IIEF-5 or IIEF-EF.
• Acceptability of the intervention.
Method and timing of outcome measurement
• Self-reported potency
◦ Number or percentage of participants achieving self-
reported potency after RP defined as an erection firm enough
and of sufficient duration to have sexual intercourse.
• Erectile function
◦ Number or percentage of participants achieving
potency after RP according to IIEF-EF and IIEF-5 scores (Rosen
1997). We defined achieving potency as IIEF-EF of 19 or greater
(mild ED) and IIEF-5 of 17 or greater (no ED).
• Serious adverse events
◦ Rate of participants who experienced at least one
serious adverse events using an erectile aid (using the NCI
Common Terminology Criteria for Adverse Events (CTCAE)
reporting; grades 3 to 5) (National Cancer Institute). If the study
authors of eligible studies did not use the CTCAE system, we
judged the adverse events by severity using the available
information described in the studies.
• Sexual QoL
◦ Mean change assessed with validated questionnaires
such as sexual domain of Expanded Prostate Cancer Index
Composite (EPIC) (Wei 2000; Szymanski 2010; Chang 2011).
• Treatment discontinuation
◦ Defined as treatment discontinuation from any cause
at any time after participants were randomised to intervention/
comparator groups.
• International Index of Erectile Function (IIEF) or IIEF-5
◦ Mean change or final value, measured as EF domain of
IIEF or total score of IIEF-5 questionnaire (Rosen 1997).
• Acceptability of the intervention
◦ Evaluated by Treatment Acceptability Questionnaires
(TAQ) (Hunsley 1992).
We considered clinically important difference for the review out-
comes to rate quality of the evidence for imprecision in the ’Sum-
mary of findings’ tables (Jaeschke 1989; Johnston 2013). There
was no reported threshold in self-reported potency, erectile func-
tion, serious adverse events, treatment discontinuation, and TAQ.
We considered the clinically important difference for self-reported
potency, erectile function, serious adverse events, treatment dis-
continuation and TAQ for acceptability of the intervention as rel-
ative risk reduction of at least 25% (Guyatt 2011a). We used the
minimal clinically important difference (MCID) of sexual domain
of EPIC of 10 points (Skolarus 2015). We considered the MCID
in the erectile function domain score of IIEF of four (Rosen 2011).
We also considered IIEF-5 of over five points as MCID (Spaliviero
2010).
We planned to assess the outcomes as short-term and long-term
outcomes.
• Up to and including 12 months postintervention (short-
term).
• More than 12 months postintervention (long-term).
’Summary of findings’ tables
Wepresented ’Summary of findings’ tables reporting the following
outcomes listed according to priority.
• Self-reported potency.
• Erectile function.
• Serious adverse events.
• Sexual QoL.
• Treatment discontinuation.
Search methods for identification of studies
Electronic searches
We initially searched the following sources from inception of each
database to 3 January 2018 (see Appendix 1).
• The Cochrane Library (via Wiley; for the search strategy)
◦ Cochrane Database of Systematic Reviews.
◦ Cochrane Central Register of Controlled Trials.
◦ Database of Abstracts of Reviews of Effects.
◦ Health Technology Assessment Database.
• MEDLINE (via Ovid).
• Embase (via Ovid).
• CINAHL.
• PsycINFO.
Searching other resources
• We examined the reference lists of relevant obtained
articles, systematic reviews and clinical practice guidelines to
check for additional related published and unpublished studies.
• We searched the Conference Proceedings Citation Index
(available through the Web of Science database). Additionally,
we searched specific conference proceedings for the British
Association of Urological Surgeons (BAUS); European
Association of Urology (EAU) and American Urological
Association (AUA) (from 2008 to June 2017). We selected 2008
as a cut-off as most conference proceedings were available on
international urological associations’ websites from 2008
onwards.
• We searched consensus papers and proceedings from
specialist meetings (e.g. Sexual Function Health Council of the
American Foundation for Urologic Disease).
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• We planned to contact experts in the field to enquire about
any relevant clinical trials or journal articles that were not listed
in other sources.
• We attempted to contact drug manufacturers, to enquire
about any relevant trials or journal articles that were not listed in
other sources.
Additionally, we searched the following central registers of clinical
trials on 6 June 2018 to identify any unpublished, ongoing or
proposed new trials:
• World Health Organization International Clinical Trials
Registry (apps.who.int/trialsearch/);
• Current Controlled Trials ( www.controlled-trials.com/);
• UK Clinical Research Network Portfolio Database (
public.ukcrn.org.uk/search/);
• UK Clinical Trials Gateway ( www.ukctg.nihr.ac.uk/
default.aspx);
• ClinicalTrials.gov register ( www.clinicaltrials.gov/);
• Current Controlled Trials ( ISRCTN Register) (
www.controlled-trials.com/mrct/);
• ClinicalStudyResults.org ( www.clinicalstudyresults.org).
Data collection and analysis
Selection of studies
We used Covidence to identify and remove potential duplicate
records. Two review authors (YP, MS) independently scanned the
abstract, title, or both, of remaining records retrieved, to deter-
mine which records should be assessed further. Two review au-
thors (YP, MS) investigated all potentially relevant records as full
text, mapped records to studies, and classified studies as included
studies, excluded studies, studies awaiting classification or ongo-
ing studies, in accordance with the criteria in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). We
resolved any discrepancies through consensus or recourse to a third
review author (PD). If resolution of a disagreement was not pos-
sible, we designated the study as ’awaiting classification’ and we
contacted study authors for clarification. We documented reasons
for exclusion of studies that may have reasonably been expected to
be included in the review in the Characteristics of excluded studies
table. Studies were included regardless of whether outcomes were
reported in a useable way. Any studies whereby intervention and
comparator groups were not compared at time of study end-point
and outcome assessment in a fair manner were excluded. For study
inclusion, both intervention and comparator arms had to, at the
time of outcome assessment, be receiving no intervention (i.e. no
treatment) or receiving the same intervention. If this was a PDE5I,
the same dose and dosing schedule should have been used. We
presented an adapted PRISMA flow diagram showing the process
of study selection (Liberati 2009).
Data extraction and management
Two review authors (YP, JJH) independently extracted data using
a form based on the standardised Cochrane data extraction form.
We performed a pilot test run of the data abstraction form in
advance to confirm its usability.
For studies that fulfilled the inclusion criteria, two review authors
(YP, JJH) independently abstracted the following information,
which we provided in the Characteristics of included studies table:
• study design;
• study dates (or report if these were not made available);
• participant details and baseline demographics;
• inclusion and exclusion criteria;
• number of participants by study/study arm;
• details of the intervention such as timing and dosage;
• definitions of outcomes, details of outcomes and how/when
they were measured, as well as any relevant subgroups;
• study funding sources;
• declarations of interest by the investigators.
We resolved any disagreements regarding study characteristics or
outcome measures by discussion, or if required, by consultation
with a third review author (PD).
Assessment of risk of bias in included studies
We used the Cochrane tool for assessing risk of bias to objectively
assess the included studies (Jüni 2001;Higgins 2011a). Two review
authors (YP, JH) independently assessed the risk of bias of each
included study. We resolved disagreements by consensus, or by
consultation with a third review author (PD). We judged the risk
of bias on an outcome-specific basis as ’low risk,’ high risk’ or
’unclear risk’ for each of the following individual items:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessors (detection bias);
• incomplete outcome reporting (attrition bias);
• selective outcome reporting;
• other biases.
We judged risk of bias domains and evaluated individual bias items
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a). We presented a ’Risk of bias’ sum-
mary figure to illustrate these findings (Figure 1; Figure 2).
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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For selection bias (random sequence generation and allocation
concealment), we evaluated risk of bias at a trial level.
For performance bias (blinding of participants and personnel), we
considered all outcomes to be susceptible to performance bias and
assessed this individually per outcome.
For detection bias (blinding of outcome assessment), we grouped
outcomes as susceptible to detection bias (subjective) or not sus-
ceptible to detection bias (objective) outcomes.
We defined the following outcomes as subjective outcomes:
• self-reported potency;
• erectile function;
• serious adverse events;
• sexual QoL;
• IIEF;
• acceptability of the intervention.
We defined the following outcomes as objective outcomes:
• treatment discontinuation.
We initially assessed attrition bias (incomplete outcome data) on a
per-outcome basis but created groups of outcomes based on similar
reporting characteristics.
For reporting bias (selective reporting), we evaluated risk of bias
on a trial level.
We further summarised the risk of bias across domains for each
outcome in each included study, as well as across studies and do-
mains for each outcome, in accordance with the approach for sum-
mary assessments of the risk of bias presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
Measures of treatment effect
We expressed dichotomous data as risk ratios (RRs) with 95%
confidence intervals (CIs). We expressed continuous data as mean
differences (MDs) with 95% CIs unless different studies used dif-
ferent measures to assess the same outcome, in which case we used
standardised mean differences (SMDs).
Unit of analysis issues
The unit of analysis was the individual participant. For cross-over
trials or trials withmore than two intervention groups, we planned
to incorporate these study designs in meta-analyses in accordance
with guidance provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011b).
Dealing with missing data
We attempted to obtain missing data from study authors and per-
formed intention-to-treat analyses if data were available; we oth-
erwise performed available-case analyses. We investigated attrition
rates (e.g. dropouts, losses to follow-up and withdrawals), and crit-
ically appraised issues of missing data. We did not impute missing
data.
Assessment of heterogeneity
We identified heterogeneity (inconsistency) through visual inspec-
tion of the forest plots to assess the amount of overlap of CIs, and
the I2 statistic, which quantifies inconsistency across studies, to
assess the impact of heterogeneity on the meta-analysis (Higgins
2002; Higgins 2003). We interpreted the I2 statistic as follows:
• 0% to 40%: may not be important;
• 30% to 60%: may indicate moderate heterogeneity;
• 50% to 90%: may indicate substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
When we found heterogeneity, we attempted to determine possi-
ble reasons for this by examining individual study and subgroup
characteristics. In the event of excessive heterogeneity unexplained
by subgroup analyses, we did not report study results as the pooled
effect estimate in a meta-analysis but provided a narrative descrip-
tion of the results of each study.
Assessment of reporting biases
If we included 10 studies or more investigating a particular out-
come, we planned to use funnel plots to assess small-study effects.
Several explanations can be offered for the asymmetry of a funnel
plot, including true heterogeneity of effect with respect to trial size,
poor methodological design (and hence bias of small trials) and
publication bias (Egger 1997; Sterne 2011). However, all compar-
isons in this review include fewer than 10 RCTs.
Data synthesis
We combined data from trials that were sufficiently similar and of
sufficient quality to provide pooled effect estimates.
We summarised data using a random-effects model (Wood 2008).
We interpreted random-effects meta-analyses with due consider-
ation of the whole distribution of effects. In addition, we per-
formed statistical analyses according to the guidelines contained
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c). For dichotomous outcomes, we used the Man-
tel-Haenszel method; for continuous outcomes, we used the in-
verse variance method. We used Review Manager 5 to perform
analyses (Review Manager 2014).
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Subgroup analysis and investigation of heterogeneity
We expected the following variables to be potential sources of het-
erogeneity and, therefore, planned to perform the following sub-
group analyses to determine potential qualitative or quantitative
interactions of the following subgroups with the effect estimate.
• Nerve-sparing approach (none versus unilateral or bilateral,
partial or complete nerve-sparing) since it may affect the
potential for recovery.
• Age of participants (under 65 years versus 65 years or
older); older men may have diminished recovery potential.
• Baseline erectile function scores (IIEF-5: 17 to 21 versus 22
to 25 or IIEF: 19 to 24 versus 25 to 30); men with diminished
baseline erectile function may have diminished recovery
potential.
Subgroup analyses of the nerve-sparing approach are important to
determine whether differences exist in effect estimate, if any, of pe-
nile rehabilitation strategies on erectile function recovery follow-
ing RP between the subgroups. Age and baseline erectile function
scores are important covariates that can affect the degree of erec-
tile function recovery offered by the penile rehabilitation strate-
gies under investigation, and, therefore, it is important to evaluate
these in separate subgroup analyses.
Sensitivity analysis
Weplanned to perform sensitivity analyses to explore the influence
of the following factors (when applicable) on effect sizes.
• Restricting the analysis by taking into account risk of bias,
by excluding studies at ’high risk’ or ’unclear risk’ of bias.
• Restricting the analysis by taking into account washout
effect, by excluding studies without washout at outcome
assessment.
’Summary of findings’ tables
We presented the overall quality of evidence (QoE) for each out-
come according to the GRADE approach, which takes into ac-
count five criteria related to internal validity (risk of bias, inconsis-
tency, imprecision, publication bias) and external validity (direct-
ness of results) (Guyatt 2011b).Two review authors (YP, JH) inde-
pendently rated the QoE for each outcome as ’high,’ ’moderate,’
’low’ or ’very low;’ we resolved discrepancies by consensus, or, if
needed, by arbitrationby a third review author (PD).Wepresented
a summary of the evidence for the main outcomes in ’Summary
of findings’ tables, which provide key information about the best
estimate of the magnitude of the effect, in relative terms and abso-
lute differences for each relevant comparison of alternative man-
agement strategies; numbers of participants and studies addressing
each important outcome; and the rating of the overall confidence
in effect estimates for each outcome (Schünemann 2011). This
was performed in GRADEpro GDT.
R E S U L T S
Description of studies
Results of the search
We identified the 3542 records through searching electronic
databases, trial registries and handsearching abstract proceedings
of relevant meetings since their inception. We identified three
other relevant records (Cavallini 2005; Nehra 2005; Seo 2014)
by searching the reference lists of CADTH guideline (CADTH
2017). After removal of 2047 duplicates, we screened the titles and
abstracts of 1498 records, and excluded 1452 records as evidently
irrelevant. We screened 46 studies for full-text eligibility, and ex-
cluded 24 studies that did not meet the inclusion criteria or were
not relevant to the question under trial. We included eight studies
(22 records) in the review. We identified no studies as awaiting
classification or part of an ongoing trial. The flow of literature
through the assessment process is shown in the PRISMA flowchart
(Figure 3).
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Figure 3. Study flow diagram.
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Included studies
Details of included studies are presented elsewhere (see
Characteristics of included studies; Table 1; Table 2).
Source of data
We included eight published studies. All studies were identified
through our electronic database search and were published in En-
glish.
Study design and settings
All included studies were parallel randomised-controlled trials.
Five of seven studies were reported as “double-blinded” (Montorsi
2008; Padma-Nathan 2008; Pavlovich 2013; Montorsi 2014;
Kim 2016). The participants and investigators were blinded in
one study (Montorsi 2014) and participants and personnel were
blinded in one study (Kim 2016). Montorsi 2008 blinded par-
ticipant, personnel, and investigator. Two studies were reported
to be “double-blinded” but it was not clear who was blinded
(Padma-Nathan 2008; Pavlovich 2013). One study was an open
label trial (McCullough 2010). The remaining trials had no in-
formation regarding blinding (Pace 2010; Aydogdu 2011). All in-
cluded trials had a washout period (treatment discontinuation for
all randomised participants) before the assessment of outcomes.
All studies were likely conducted in an outpatient clinic setting.
Most of the included studies were performed in theUS andEurope
(Montorsi 2008; Padma-Nathan 2008; McCullough 2010; Pace
2010; Aydogdu 2011; Pavlovich 2013; Montorsi 2014), except
one study which was performed in Asia (Kim 2016). Four trials
were multicentre trials (Montorsi 2008; Padma-Nathan 2008;
McCullough 2010; Montorsi 2014). The studies were performed
from year 1999 to 2012.
Participants
We included 1699 randomised participants, of which 1223 par-
ticipants finished the trial. The mean age was 56.7 years and mean
prostate-specific antigen (PSA) was 4.98 ng/mL. Only three stud-
ies reported pathological Gleason score and tumour stage (Pace
2010; Pavlovich 2013; Kim 2016). Pathological Gleason score
ranged from six to eight. Kim 2016 included one participant with
T3 disease. The remaining studies included T1 and T2 disease.
Bilateral nerve-sparing RP was performed in most of the included
studies (Montorsi 2008; Padma-Nathan 2008;McCullough 2010;
Pace 2010; Aydogdu 2011;Montorsi 2014). Kim2016 performed
bilateral nerve-sparing procedure except in one participant who
underwent unilateral nerve sparing. Pavlovich 2013 used a nerve-
sparing procedure but did not describe whether it was unilateral
or bilateral. RARP or LRP was performed in three of eight trials
(McCullough 2010; Pavlovich 2013; Kim 2016).
Major exclusion criteria included known risk factors for EDsuch as
diabetes mellitus and cardiovascular disease, prior treatment with
experimental interventions, neoadjuvant or adjuvant treatment
with other prostate cancer therapies such as radiotherapy or hor-
mone therapy and the presence of ED at baseline. Padma-Nathan
2008 additionally described sleep disorder as an exclusion cri-
terion. One study did not describe exclusion criteria (Aydogdu
2011).
Interventions and comparators
Sildenafil was used in all studies except three studies (vardenafil:
Montorsi 2008; tadalafil: Aydogdu 2011; Montorsi 2014). Daily
sildenafil was administrated as an oral dose of 50mg (McCullough
2010; Pavlovich 2013; Kim 2016) or 100 mg (Padma-Nathan
2008). One study did not specify the exact dose of sildenafil (Pace
2010; both 50 mg or 100 mg). Daily vardenafil was adminis-
trated as an oral dose of 10 mg but decreased to 5 mg, if required
(Montorsi 2008). Daily tadalafil was administrated as an oral dose
of 5 mg (Montorsi 2014). On-demand sildenafil was also admin-
istrated as an oral dose of 50 mg (Padma-Nathan 2008; Pavlovich
2013) or 100 mg (Kim 2016). On-demand vardenafil was used
as a flexible-dose (starting at 10 mg with the option to titrate to
5 mg or 20 mg) (Montorsi 2008). Tadalafil was administrated as
an oral dose of 20 mg three times a week Aydogdu 2011 or on-
demand (Montorsi 2014).
Daily prostaglandin E1 was administrated intraurethrally (
McCullough 2010). The drug dose was titrated (125 µg followed
by 250 µg) during study period.
Placebo was used as comparators in three studies (Montorsi 2008;
Padma-Nathan 2008;Montorsi 2014). Two studies used ’no treat-
ment’ as a comparator (Pace 2010; Aydogdu 2011).
The duration of intervention ranged from eight weeks to 12
months. All interventions were administrated within one month
after surgery in all included studies. The duration of washout
ranged from four weeks to eight weeks in six of the included
studies (Montorsi 2008; Padma-Nathan 2008;McCullough 2010;
Pavlovich 2013; Montorsi 2014; Kim 2016). Aydogdu 2011 ad-
ministrated the intervention for six months and assessed the out-
comes at 12 months after surgery. One study administered the in-
tervention for eight weeks and assessed the outcomes at 24 weeks
after surgery (Pace 2010).
Comparisons
We included three comparisons in this review, which were in-
formed by eight studies. Two studies were three-armed trials and
contributed to two comparisons each.
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• Five studies compared scheduled (daily or twice a week)
PDE5I use to placebo or no treatment (Aydogdu 2011; Montorsi
2008; Montorsi 2014; Pace 2010; Padma-Nathan 2008).
• Four studies compared daily PDE5I to on-demand PDE5I
(Montorsi 2008; Pavlovich 2013; Montorsi 2014; Kim 2016),
and
• One study compared daily PDE5I to daily intraurethral
prostaglandin E1 (McCullough 2010).
Tables 1 and 2 (Table 1; Table 2) provide further details about the
specifics of the comparison.
Outcomes
We identified the primary outcomes in each of the included stud-
ies for all comparisons of PDE5I (i.e. versus placebo/no treatment,
on-demand use and intraurethral prostaglandin E1). For self-re-
ported potency, we used different questionnaires or definitions for
outcome measurement such as Rigiscan (Kim 2016); participant-
reported intercourse success rate (McCullough 2010); Sexual En-
counter Profile (SEP) question (Montorsi 2008; Aydogdu 2011;
Montorsi 2014); and potency rate (not defined) (Pace 2010). Re-
turn to normal erectile function was defined as IIEF-EF greater
than 22 (Montorsi 2008; Pavlovich 2013; Montorsi 2014; Kim
2016); IIEF-EF greater than 26 and greater than 17 (McCullough
2010); IIEF-EF 26 or greater (Aydogdu 2011); IIEF question 3
and 4 of 8 or greater (Padma-Nathan 2008); IIEF-EF (not defined)
(Pace 2010). Given that none of included studies reported serious
adverse events using CTCAE, we used the available information
described in the studies. No trial reported on our predefined sec-
ondary outcomes of acceptability of the intervention. Other sec-
ondary outcomes were reported in at least one of the included
studies.
We used the outcomes that were assessed after washout period to
make a fair comparison. For long-term follow-up, we used the
sexual QoL and treatment discontinuation outcomes that were
assessed after the open-label period (with all participants taking
on-demand PDE5I for that time period).
Funding sources and conflicts of interest
Four studies were supported by pharmaceutical companies (
Montorsi 2008; Padma-Nathan 2008; Montorsi 2014; Kim
2016), and one study explicitly reported no funding source
(Pavlovich 2013). Three studies did not disclose funding sources
(McCullough 2010; Pace 2010; Aydogdu 2011). Four stud-
ies reported having relationships with pharmaceutical compa-
nies (Montorsi 2008; Padma-Nathan 2008; McCullough 2010;
Montorsi 2014), and three studies reported no conflicts of inter-
ests (Pace 2010; Aydogdu 2011; Pavlovich 2013). One study did
not disclose whether conflicts of interest were present (Kim 2016).
Excluded studies
We assessed 46 full-text records and excluded 24 studies (see
Characteristics of excluded studies table).
Studies awaiting classification
We found no studies awaiting classification.
Ongoing studies
We found no ongoing studies.
Risk of bias in included studies
See Figure 1; Figure 2.
Allocation
Random sequence generation
Two studies were at low risk of bias (Montorsi 2008; Padma-
Nathan 2008). The remaining studies were at unclear risk of bias.
Allocation concealment
Only one study was at low risk of bias (Montorsi 2008), and the
remaining studies were at unclear risk of bias.
Blinding
Blinding of participants and personnel
We rated five studies at low risk of bias (Montorsi 2008; Padma-
Nathan 2008; Pavlovich 2013; Montorsi 2014; Kim 2016). We
judged one study at high risk of bias (McCullough 2010), and the
remaining studies at unclear risk of bias.
Blinding of outcome assessment
Subjective outcomes: self-reported potency, erectile function,
serious adverse events, sexual quality of life, IIEF and
acceptability of the intervention
We rated four studies at low risk of bias (Montorsi 2008; Padma-
Nathan 2008; Pavlovich 2013; Montorsi 2014). We judged one
study at high risk of bias (McCullough 2010), and the remaining
studies at unclear risk of bias.
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Objective outcomes: treatment discontinuation
We rated all studies at low risk of bias as objective outcomes are
unlikely to be affected by lack of blinding.
Incomplete outcome data
Self-reported potency
We rated two studies at low risk of bias (Montorsi 2014; Kim
2016).We judged four studies at high risk of bias (Montorsi 2008;
Padma-Nathan 2008; McCullough 2010; Pavlovich 2013), and
the remaining studies at unclear risk of bias.
Erectile function/International Index of Erectile Function
We rated two studies at low risk of bias (Montorsi 2014; Kim
2016).We judged four studies at high risk of bias (Montorsi 2008;
Padma-Nathan 2008; McCullough 2010; Pavlovich 2013), and
the remaining studies at unclear risk of bias.
Serious adverse events
We rated four studies at low risk of bias (Montorsi 2008; Padma-
Nathan 2008; Pace 2010; Pavlovich 2013), and the remaining
studies at unclear risk of bias.
Sexual quality of life
We rated one study at low risk of bias (Montorsi 2014), and the
remaining studies at unclear risk of bias.
Treatment discontinuation
We rated six studies at low risk of bias (Montorsi 2008; Padma-
Nathan 2008; Pace 2010; Pavlovich 2013; Montorsi 2014; Kim
2016), and the two remaining studies at unclear risk of bias (
Aydogdu 2011 McCullough 2010).
Acceptability of the intervention
None of the included studies reported acceptability of the inter-
vention; therefore, we rated all studies at unclear risk of bias.
Selective reporting
We rated one study at low risk of bias (Montorsi 2008), and the
remaining studies at unclear risk of bias.
Other potential sources of bias
We rated seven studies at low risk of bias (Montorsi 2008;
McCullough 2010; Pace 2010; Aydogdu 2011; Pavlovich 2013;
Montorsi 2014; Kim 2016). We judged one study at high risk of
bias due to premature termination as a result of lack of efficacy of
the intervention (Padma-Nathan 2008).
Effects of interventions
See: Summary of findings for the main comparison Scheduled
PDE5I compared to on demand placebo or no treatment for
post-prostatectomy erectile dysfunction (short-term); Summary
of findings 2 Scheduled PDE5I compared to on demand placebo
or no treatment for post-prostatectomy erectile dysfunction (long-
term); Summary of findings 3 Scheduled PDE5I compared to
on demand PDE5I for post-prostatectomy erectile dysfunction
(short-term); Summary of findings 4 Scheduled PDE5I
compared to on demand PDE5I for post-prostatectomy erectile
dysfunction (long-term); Summary of findings 5 Scheduled
PDE5I compared to scheduled intraurethral prostaglandin E1 for
post-prostatectomy erectile dysfunction (short term)
1. Scheduled phosphodiesterase 5 inhibitor versus placebo
or no treatment
We included five studies comparing scheduled PDE5I versus
placebo or no treatment short-term (Montorsi 2008; Padma-
Nathan 2008; Pace 2010; Aydogdu 2011; Montorsi 2014). We
included two studies comparing daily PDE5I versus placebo long-
term (Montorsi 2008; Montorsi 2014).
1.1. Self-reported potency
We included four RCTs with 628 participants in the short-term
analysis (scheduled PDE5I 307, placebo or no treatment 321)
(Montorsi 2008; Pace 2010; Montorsi 2014). Three studies used
SEP diary question 3 (change from baseline in ’Yes’ answers to
questions) (Montorsi 2008; Aydogdu 2011; Montorsi 2014), and
one study used self-reported potency rate that was not further
defined in the methods section of the study (Pace 2010).
Scheduled PDE5I may result in little to no difference in self-re-
ported potency (RR1.13, 95%CI 0.91 to 1.41; I2 = 33%; Analysis
1.1), which corresponds to 47 more men with self-reported po-
tency per 1000 (95% CI 33 fewer to 149 more), but we are very
uncertain of this finding. We rated the QoE as very low, down-
grading for study limitations, indirectness and imprecision.
We found no studies that reported long-term data for self-reported
potency.
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1.2. Erectile function
We included five RCTs with 757 participants in the short-term
analysis (scheduled PDE5I 385, placebo or no treatment 372)
(Montorsi 2008; Padma-Nathan2008; Pace 2010; Aydogdu2011;
Montorsi 2014). One study reported the proportion of partici-
pants with IIEF-EF greater than 25 (no dysfunction) (Aydogdu
2011). Two studies reported the proportion of participants with
IIEF-EF greater than 21 (mild to no dysfunction) (Montorsi 2008;
Montorsi 2014), and one study reported the proportion of par-
ticipants who scored 8 or greater on Qquestion 3 and question 4
of the IIEF and also answered ’yes’ to the question “Over the past
4 weeks, have your erections been good enough for satisfactory
sexual activity?” after treatment (Padma-Nathan 2008).
Scheduled PDE5I may result in little to no difference in erectile
function (RR 1.11, 95% CI 0.80 to 1.55; I2 = 37%; Analysis 1.2),
which corresponds to 28 more men per 1000 (95%CI 50 fewer to
138 more) but we are very uncertain of this finding. We rated the
QoE as very low, downgrading for study limitations, indirectness
and imprecision.
We found no studies that reported long-term data for erectile
function.
1.3. Serious adverse events
We included three RCTs with 443 participants in the analysis
(scheduled PDE5I 240, placebo or no treatment 203) (Padma-
Nathan 2008; Pace 2010; Montorsi 2014).
Scheduled PDE5I may result in less serious adverse events (RR
0.32, 95% CI 0.11 to 0.94; I2 = 0%; Analysis 1.3), which corre-
sponds to 44 fewer men per 1000 (95% CI 57 fewer to 4 fewer),
but we considered this to have low biological plausibility and to
likely represent a chance finding. We rated the QoE as low, down-
grading for study limitations and imprecision.
We found no studies that reported long-term data for serious ad-
verse events.
1.4. Sexual quality of life
We found no studies that reported short-termdata for sexual QoL.
We included one RCT with 280 participants in the analysis (daily
PDE5I 139, placebo 141) that reported long-term data (Montorsi
2014).
Scheduled PDE5I likely results in little to no difference in sexual
QoL long term (MD3.20 points, 95%CI -5.91 to 12.31; Analysis
1.6).We rated theQoE asmoderate, downgrading for imprecision.
1.5. Treatment discontinuation
We included three RCTs with 443 participants in the short-term
analysis (scheduled PDE5I 240, placebo or no treatment 203)
(Padma-Nathan 2008; Pace 2010; Montorsi 2014).
Scheduled PDE5I appears to result in little to no difference on
treatment discontinuation (RR 0.98, 95% CI 0.72 to 1.34; I2 =
0%; Analysis 1.4),which corresponds to 5 fewer men per 1000
(95%CI 69 fewer to 84 more), but we are very uncertain of this
finding. We rated the QoE as very low, downgrading for study
limitations and imprecision.
We included one RCT with 420 participants in the long-term
analysis (daily PDE5I 210, placebo 210) (Montorsi 2008).
Scheduled PDE5I likely results in little to no difference in rates
of treatment discontinuation (RR 1.12, 95% CI 0.85 to 1.48;
Analysis 1.7), which corresponds to 37 more men per 1000 who
discontinued treatment (95%CI 46 fewer to 149 more). We rated
the QoE as moderate, downgrading for imprecision.
1.6. International Index of Erectile Function
We included two RCTs with 356 participants in the short-term
analysis (scheduled PDE5I 190, placebo or no treatment 166)
(Padma-Nathan 2008; Montorsi 2014). We used the change from
baseline inMontorsi 2014 and final value in Padma-Nathan 2008.
Scheduled PDE5I may result in little to no difference in IIEF-EF
domain score (RR 2.09, 95% CI -1.85 to 6.03; I2 = 64%; Analysis
1.5). We rated the QoE as low, downgrading for study limitations
and imprecision.
We found no studies that reported long-term data for IIEF.
1.7. Acceptability of the intervention
We found no studies that reported acceptability of the intervention
either short-term or long-term.
Subgroup analysis
We were unable to perform any subgroup analyses due to no rel-
evant data in the included studies.
Sensitivity analysis
As we rated only one study at low risk of bias (Montorsi 2014),
and all included studies had a washout period (Montorsi 2008;
Padma-Nathan 2008; Montorsi 2014) or no treatment period (
Pace 2010), we were unable to perform any meaningful sensitivity
analyses.
2. Scheduled phosphodiesterase 5 inhibitor versus on-
demand phosphodiesterase 5 inhibitor
We included two studies comparing daily PDE5I versus on-de-
mand PDE5I short-term (Montorsi 2008; Montorsi 2014).
We included four studies comparing daily PDE5I versus on-
demand PDE5I long-term (Montorsi 2008; Pavlovich 2013;
Montorsi 2014; Kim 2016).
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2.1. Self-reported potency
We included two RCTs with 532 participants in the short-term
analysis (daily PDE5I 255, on-demand PDE5I 277) (Montorsi
2008; Montorsi 2014). We used the results of SEP diary question
3 to evaluate self-reported potency.
Daily PDE5I may result in little to no difference in on self-re-
ported potency short-term (RR 0.97, 95% CI 0.62 to 1.53; I2 =
67%; Analysis 2.1), which corresponds to nine fewer men with
self-reported short-term potency per 1000 (95% CI 119 fewer to
166 more), but we were very uncertain of this finding. We rated
the QoE as very low, downgrading for study limitations and im-
precision.
We included one RCT with 94 participants in the long-term anal-
ysis (daily PDE5I 47, on-demand PDE5I 47) (Kim 2016). While
Kim 2016 reported Rigiscan as objective assessment of erectile
function; we used these data as self-reported potency.
Daily PDE5I may result in little to no difference in self-reported
potency long term (RR 1.00, 95% CI 0.60 to 1.67; Analysis 2.6),
which corresponds to zero fewermen with self-reported long-term
potency per 1000 (95% CI 153 fewer to 257 more) but we are
very uncertain of this finding. We rated the quality of evidence as
very low, downgrading for study limitations and imprecision.
2.2. Erectile function
We included two RCTs with 573 participants in the short-term
analysis (daily PDE5I 282, on-demand PDE5I 291) (Montorsi
2008; Montorsi 2014). All included studies reported the propor-
tion of participants with IIEF-EF greater than 21 (mild to no dys-
function) after treatment.
Daily PDE5Imay result in little to no difference in short term erec-
tile function (RR 1.00, 95% CI 0.65 to 1.55; I2 = 49%; Analysis
2.2), which corresponds to zero fewer men with short-term erec-
tile dysfunction per 1000 (95% CI 79 fewer to 125 more), but we
were very uncertain of this finding. We rated the QoE as very low,
downgrading for study limitations and imprecision.
We included two RCTs with 168 participants in the long-term
analysis (daily PDE5I 83, on-demandPDE5I85) (Pavlovich 2013;
Kim 2016). All included studies reported the proportion of par-
ticipants with IIEF-EF greater than 21 (mild to no dysfunction).
Daily PDE5I appears to result in little to no difference in erectile
function long term (RR 0.74, 95% CI 0.48 to 1.14; I2 = 0%;
Analysis 2.7), which corresponds to 119 fewermenwith long-term
erectile dysfunction per 1000 (95% CI 239 fewer to 64 more),
but we were very uncertain of this finding. We rated the QoE as
very low, downgrading for study limitations and imprecision.
2.3. Serious adverse events
We included one RCT with 282 participants in the short-term
analysis (daily PDE5I 139, on-demand PDE5I 143) (Montorsi
2014).
Daily PDE5I appeared to result in little to no difference in seri-
ous adverse events short term (RR 0.69, 95% CI 0.12 to 4.04;
Analysis 2.3), which corresponds to seven fewer men with short-
term serious adverse events (95% CI 18 fewer to 64 more) but we
are very uncertain of this finding. We rated the QoE as very low,
downgrading for study limitations and imprecision.
2.4. Sexual quality of life
We found no studies that reported short-term outcomes for sexual
QoL.
We included one RCT with 281 participants in the long-term
analysis (daily PDE5I 139, on-demand PDE5I 142) (Montorsi
2014).
Daily PDE5I likely results in little or no difference in sexual QoL
long-term (MD4.00 points, 95%CI -4.84 to 12.84; Analysis 2.9).
We rated the QoE as moderate, downgrading for imprecision.
2.5. Treatment discontinuation
We included one RCT with 282 participants in the short-term
analysis (daily PDE5I 139, on-demand PDE5I 143) (Montorsi
2014).
Daily PDE5I may result in little to no difference in treatment dis-
continuation short-term (RR 1.35, 95% CI 0.85 to 2.12; Analysis
2.4), which corresponds to 63 more men who discontinued treat-
ment (95% CI 36 fewer to 203 more). We rated the QoE as low,
downgrading for study limitations and imprecision.
We included three RCTs with 612 participants in the long-term
analysis (daily PDE5I 307, on-demand PDE5I 305) (Pavlovich
2013; Montorsi 2014; Kim 2016).
Daily PDE5I may result in little to no difference in treatment dis-
continuation long-term (RR 1.09, 95% CI 0.86 to 1.38; Analysis
2.10), which corresponds to 27moremenwho discontinued treat-
ment (95% CI 41 fewer to 112 more), but we are very uncertain
of this finding. We rated the QoE as very low, downgrading for
study limitations, indirectness and imprecision.
2.6. International Index of Erectile Function
We included one RCT with 281 participants in the short-term
analysis (daily PDE5I 139, placebo 142) (Montorsi 2014).
Daily PDE5I results in little or no difference in IIEF-EF domain
score short-term (MD 0.16, 95% CI -0.15 to 0.47; Analysis 2.5).
We rated the QoE as high.
We found no studies that reported long-term outcomes.
2.7. Acceptability of the intervention
We found no studies that reported short-term or long-term out-
comes.
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Subgroup analysis
We were unable to perform any subgroup analyses due to no rel-
evant data in the included studies.
Sensitivity analysis
As we rated only one study at low risk of bias (Montorsi 2014),
and all included studies had washout periods, we were unable to
perform sensitivity analyses.
3. Daily phosphodiesterase 5 inhibitor versus daily
intraurethral prostaglandin E1 (short-term)
We included one study with 156 participants (on-demand PDE5I
59, placebo 97) comparing daily PDE5I versus intraurethral
prostaglandin E1 with short-term follow-up (McCullough 2010).
We found no studies with long-term follow-up.
3.1. Self-reported potency
McCullough 2010 reported the proportion of participants who
had successful sexual intercourse short-term.
Daily PDE5I appears to result in little to no difference in self-
reported potency (RR 1.10, 95% CI 0.79, to 1.52; Analysis 3.1),
which corresponds to 46 more men per 1000 (95% CI 97 fewer
to 241 more) but we were very uncertain of this finding. We
rated the QoE as very low, downgrading for study limitations and
imprecision.
3.2. Erectile function
McCullough 2010 reported erectile function based on IIEF-EF
greater than 26 (no dysfunction) and IIEF-EF greater than 17
(moderate to no dysfunction).
Daily PDE5I may result in a small improvement in erectile func-
tion (IIEF-EF greater than 26: RR 1.64, 95% CI 0.84 to 3.20;
Analysis 3.2; IIEF-EF greater than 17: RR 1.20, 95% CI 0.79 to
1.81; Analysis 3.3), which corresponds to 92 more men per 1000
(95% CI 23 fewer to 318 more), but we are very uncertain of this
finding. We rated the QoE as very low, downgrading for study
limitations and imprecision.
3.3. Serious adverse events
We found no studies that reported serious adverse events.
3.4. Sexual quality of life
We found no studies that reported sexual QoL.
3.5. Treatment discontinuation
We found no studies that reported treatment discontinuation.
3.6. International Index of Erectile Function
We found no studies that reported IIEF.
3.7. Acceptability of the intervention
We found no studies that reported acceptability of the interven-
tion.
Subgroup analysis
We were unable to perform any subgroup analyses due to no rel-
evant data in the included studies.
Sensitivity analysis
We were unable to perform any subgroup analyses due to paucity
of included studies.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Scheduled PDE5I compared to on demand placebo or no treatment for post-prostatectomy erectile dysfunction (long- term)
Patient or population: post-prostatectomy erect ile dysfunct ion (long-term)
Setting: outpat ient clinic
Intervention: scheduled PDE5I
Comparison: on demand placebo or no treatment
Outcomes of participants
(studies)
Follow up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI)
Risk with on demand placebo
or no treatment
Risk difference with sched-
uled PDE5I
Self- reported potency - not
reported
- - - - -
Erectile function - not re-
ported
- - - - -
Serious adverse events -
not reported
- - - - -
Sexual quality of life
assessed with: Expanded
Prostate Cancer Index Com-
posite (sexual domain)
Scale f rom: 0 (worst) to 100
(best)
follow up: mean 54 weeks
280
(1 RCT)
⊕⊕⊕©
MODERATE 1
- The mean quality of lif e was
33.4
MD 3.2 higher
(5.91 lower to 12.31 higher)
Treatment discontinuation
f ollow up: mean 54 weeks
420
(1 RCT)
⊕⊕⊕©
MODERATE 1
RR 1.12
(0.85 to 1.48)
Study populat ion
310 per 1,000 37 more per 1,000
(46 fewer to 149 more)
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International Index of Erec-
tile Function - not reported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for imprecision: conf idence interval crosses assumed threshold of clinically important dif f erence.
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Scheduled PDE5I compared to on demand PDE5I for post-prostatectomy erectile dysfunction (short- term)
Patient or population: post-prostatectomy erect ile dysfunct ion (short-term)
Setting: outpat ient clinic
Intervention: scheduled PDE5I
Comparison: on demand PDE5I
Outcomes of participants
(studies)
Follow up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI)
Risk with on demand PDE5I Risk difference with sched-
uled PDE5I
Self- reported potency
assessed with: Sexual En-
counter Prof ile diary ques-
t ion 3
follow up: range 42 weeks
to 46 weeks
532
(2 RCTs)
⊕©©©
VERY LOW 123
RR 0.97
(0.62 to 1.53)
Study populat ion
314 per 1,000 9 fewer per 1,000
(119 fewer to 166 more)
Erectile function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main
follow up: range 42 weeks
to 46 weeks
573
(2 RCTs)
⊕©©©
VERY LOW 123
RR 1.00
(0.65 to 1.55)
Study populat ion
227 per 1,000 0 fewer per 1,000
(79 fewer to 125 more)
Serious adverse events
f ollow up: mean 42 weeks
282
(1 RCT)
⊕©©©
VERY LOW 14
RR 0.69
(0.12 to 4.04)
Study populat ion
21 per 1,000 7 fewer per 1,000
(18 fewer to 64 more)
Sexual quality of life - not
reported
- - - - -
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Treatment discontinuation
f ollow up: mean 42 weeks
282
(1 RCT)
⊕⊕©©
LOW 3
RR 1.35
(0.85 to 2.12)
Study populat ion
182 per 1,000 64 more per 1,000
(27 fewer to 204 more)
International Index of Erec-
tile Function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main
Scale f rom: 1 (worst: severe
ED) to 30 (best: no ED)
follow up: mean 42 weeks
281
(1 RCT)
⊕⊕⊕⊕
HIGH
- The mean internat ional Index
of Erect ile Funct ion ranged
f rom 2.38
MD 0.16 higher
(0.15 lower to 0.47 higher)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
2 Not downgraded for inconsistency despite moderate or substant ial heterogeneity given that likely not clinically meaningful.
3 Downgraded by two levels for imprecision: wide conf idence interval crosses assumed threshold of clinically important
dif f erence.
4 Downgraded by two levels for imprecision: very rare event result ing in wide conf idence interval.
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Scheduled PDE5I compared to on demand PDE5I for post-prostatectomy erectile dysfunction (long- term)
Patient or population: post-prostatectomy erect ile dysfunct ion (long-term)
Setting: outpat ient clinic
Intervention: scheduled PDE5I
Comparison: on demand PDE5I
Outcomes of participants
(studies)
Follow up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI)
Risk with on demand PDE5I Risk difference with sched-
uled PDE5I
Self- reported potency
assessed with: Rigi scan
follow up: mean 13 months
94
(1 RCT)
⊕©©©
VERY LOW 12
RR 1.00
(0.60 to 1.67)
Study populat ion
383 per 1,000 0 fewer per 1,000
(153 fewer to 257 more)
Erectile function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main
follow up: mean 13 months
168
(2 RCTs)
⊕©©©
VERY LOW 12
RR 0.74
(0.48 to 1.14)
Study populat ion
459 per 1,000 119 fewer per 1,000
(239 fewer to 64 more)
Serious adverse events -
not reported
- - - - -
Sexual quality of life
assessed with: Expanded
Prostate Cancer Index Com-
posite (sexual domain)
Scale f rom: 0 (worst) to 100
(best)
follow up: mean 54 weeks
281
(1 RCT)
⊕⊕⊕©
MODERATE 4
- The mean sexual quality of
lif e was 32.6
MD 4 higher
(4.84 lower to 12.84 higher)
2
6
P
e
n
ile
re
h
a
b
ilita
tio
n
fo
r
p
o
stp
ro
sta
te
c
to
m
y
e
re
c
tile
d
y
sfu
n
c
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Treatment discontinuation
f ollow up: range 52 weeks
to 54 weeks
612
(3 RCTs)
⊕©©©
VERY LOW 145
RR 1.09
(0.86 to 1.38)
Study populat ion
295 per 1,000 27 more per 1,000
(41 fewer to 112 more)
International Index of Erec-
tile Function - not reported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for study lim itat ions: unclear or high risk of bias in one or more domains.
2 Downgraded by two levels for imprecision: wide conf idence interval crosses assumed threshold of clinically important
dif f erence.
3 Downgraded by two levels for imprecision: very rare event result ing in wide conf idence interval.
4 Downgraded by one level for imprecision: conf idence interval crosses assumed threshold of clinically important dif f erence.
5 Downgraded by one level for indirectness: dif f erence in intervent ion at the t ime of outcome assessment (no treatment
versus on demand PDE5I).
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Scheduled PDE5I compared to scheduled intraurethral prostaglandin E1 for post-prostatectomy erectile dysfunction (short term)
Patient or population: post-prostatectomy erect ile dysfunct ion (short term)
Setting: outpat ient clinic
Intervention: scheduled PDE5I
Comparison: scheduled intraurethral prostaglandin E1
Outcomes of participants
(studies)
Follow up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI)
Risk with scheduled intrau-
rethral prostaglandin E1
Risk difference with sched-
uled PDE5I
Self- reported potency
assessed with: Intercourse
success rate
follow up: mean 11 months
156
(1 RCT)
⊕©©©
VERY LOW 12
RR 1.10
(0.79 to 1.52)
Study populat ion
464 per 1,000 46 more per 1,000
(97 fewer to 241 more)
Erectile function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main > 26
follow up: mean 11 months
156
(1 RCT)
⊕©©©
VERY LOW 12
RR 1.64
(0.84 to 3.20)
Study populat ion
144 per 1,000 92 more per 1,000
(23 fewer to 318 more)
Erectile function
assessed with: Interna-
t ional Index of Erect ile Func-
t ion-Erect ile Funct ion do-
main > 17
follow up: mean 11 months
156
(1 RCT)
⊕©©©
VERY LOW 12
RR 1.20
(0.79 to 1.81)
Study populat ion
340 per 1,000 68 more per 1,000
(71 fewer to 276 more)
Serious adverse events -
not reported
- - - - -
Sexual quality of life - not
reported
- - - - -
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Treatment discontinuation
- not reported
- - - - -
International Index of Erec-
tile Function - not reported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for study lim itat ions: unclear or high risk of bias in almost all domains.
2 Downgraded by two levels for imprecision: wide conf idence interval crosses assumed threshold of clinically important
dif f erence.
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D I S C U S S I O N
Summary of main results
This review included eight studies with 1699 randomised partic-
ipants across three comparisons. The mean participant age was
56.7 years and the preoperative PSA level was approximately 5 ng/
mL.
We only included the trials with participants who received no
treatment or the same treatment (e.g. the same type and dosage
of PDE5I) for both intervention and control group at the time of
outcome assessment to allow a fair comparison of efficacy of these
agents. This is a critical methodological aspect of this review.
We found trial evidence for two comparisons that assessed sched-
uled medication versus placebo or no treatment or on-demand use
only. Although wewere very uncertain of the result due to very low
QoE, neither suggested a benefit of a rehabilitation regimen that
relied on scheduled medication dosage over placebo/no treatment
or on-demand use only.
We found trial evidence for one comparison of different rehabil-
itation regimens, namely daily PDE5I versus daily intraurethral
prostaglandin E1. Similarly, based on very low quality evidence,
efficacy was comparable.
We found limited evidence on serious adverse events for the three
available comparisons. We found no eligible trials for any other
comparisons, such as those comparing scheduled intracavernosal
injections versus on-demand use.
We were unable to conduct any of the preplanned subgroup analy-
ses, namely based on nerve-sparing status, age and baseline erectile
function due to lack of relevant data.
Overall completeness and applicability of
evidence
Several issues impact the completeness and applicability of the
summarised evidence:
Participant population
• Almost all studies were conducted in western countries.
Given the increasing prevalence rate of prostate cancer in Asia
further studies performed in Asian countries would be valuable
in validating these findings.
• Although all studies included participants who had normal
or mild erectile function at screening and developed ED as a
result of prostatectomy, the definitions of baseline ED were
different between studies.
• We were unable to conduct any of the preplanned subgroup
analyses, namely based on nerve-sparing status, age and baseline
erectile function.
Interventions and comparators
• Included studies used different PDE5I. Given that tadalafil
20 mg has a long half-life, we combined the results with
scheduled tadalafil (twice a week; Aydogdu 2011) and daily
dosing PDE5I. These differences in the interventions may have
affected the review results.
• There were different treatment durations and follow-up
periods among included studies that contributed clinical
heterogeneity and may have affected the results of this review.
• There were no trials on several comparisons of interest, for
example scheduled versus on-demand intracavernosal injections.
Outcomes
• Even though the primary outcome of erectile function was
determined with validated questionnaires, there was clinical and/
or methodological heterogeneity among studies in how they
measured and reported these outcomes. Also studies used
different definitions of recovery of ED for outcome
measurement.
• Most included trials focused on short-term outcomes.
Given the long-lasting impact of RP on ED, such short-term
outcomes appear insufficient to provide assurance of long-term
effectiveness.
Quality of the evidence
We downgraded the QoE to very low for nearly all primary out-
comes. Issues that lowered our confidence in the estimates of the
effect were study limitations, specifically selection bias (unclear
allocation), performance and detection bias (lack of blinding for
subjective outcomes), and other biases such as attrition bias and
baseline imbalances in study characteristics.
We also downgraded for indirectness and imprecision due to dif-
ferences in methods of outcome measurements (e.g. different def-
initions of self-reported potency and recovery of erectile function
according to IIEF/IIEF-EF scores) and wide CIs.
Potential biases in the review process
Although we conducted this systematic review with a comprehen-
sive search strategy consistent with current Cochrane standards,
there was the possibility of bias.
• Despite a comprehensive search of published and
unpublished studies without language restrictions, which
included contacting the principal investigators of the existing
studies and experts in the field, we may have missed relevant
studies. This may be because they were published in non-
indexed journals or were unpublished.
• Most studies were industry-sponsored and may have been
particularly susceptible to publication bias. Given the paucity of
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studies we encountered, statistical tests for publication bias were
not meaningful.
Agreements and disagreements with other
studies or reviews
Our systematic review stands out for its high methodological stan-
dards as documented by the a priori published protocol (Philippou
2016), its comprehensive search strategy with a focus on RCTs
and its use of GRADE to rate the QoE on a per-outcome basis.
Several systematic reviews have beenpublished on this topic. These
include Tian 2017 (eight RCTs), Qiu 2016 (14 RCTs), Cui 2016
(six RCTs), Li 2014 (seven RCTs) and Wang 2014 (eight RCTs).
Universally all of these studies concluded that PDE5I were safe,
well-tolerated and reported significant improvements in the IIEF-
EF scores as compared with placebo or no treatment (Tian 2017:
short-term: MD 2.26, 95% CI 1.45 to 3.08; P < 0.00001; long-
term: MD 4.5, 95% CI 3.6 to 5.4; P < 0.00001; Qiu 2016: MD
4.89, 95% CI 4.25 to 5.53; P < 0.001; Cui 2016: MD 4.04, 95%
CI 2.87 to 5.22; P < 0.00001; Li 2014:MD 4.35, 95% CI 3.42 to
5.29; P < 0.00001; Wang 2014: MD 5.63, 95% CI 4.26 to 6.99;
P < 0.00001 in favour of the PDE5I arm.
Our review differed in two important ways.
• We focused on patient-important outcomes and rated the
QoE using GRADE on a per-outcome basis. Therefore, this
review is the first to describe the degree of certainty we can place
in these results. For the most part, this confidence was very low
indicating major uncertainty.
• Many existing reviews choose to include all existing trials
for a given comparison irrespective of whether they provided a
fair comparison when it came to outcome assessment. For
example, Tian 2017 included four, Qiu 2016 included nine, Cui
2016 included two, Li 2014 included three and Wang 2014
included five such studies, which we excluded on the basis of
inappropriate assessment of outcomes. This probably explained
the difference in our results compared to the other systematic
reviews.
Despite these results from the other reviews which concluded that
PDE5I were efficacious in restoring erectile function, there ap-
pears awareness of these methodological issues mentioned above
by the International Society of Sexual Medicine. In the guideline
document from the Fourth International Consultation for Sexual
Medicine, the authors indicated that data were conflicting as to
whether penile rehabilitation with PDE5Is improved recovery of
spontaneous erections (Salonia 2017). Our review underscores the
concern that scheduled use of PDE5I has no advantage over on
demand use, but likely increase the costs of treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence summarised in this systematic review does not pro-
vide support for penile rehabilitation after radical prostatectomy
(RP) as a means to restore erectile function to its unassisted pre-
operative state compared to no treatment or placebo or on-de-
mand treatment alone. However, it should be noted that the ev-
idence provided in this review includes studies that evaluated
only phosphodiesterase-5 inhibitors (PDE5I) and intraurethral
prostaglandin as monotherapy from the armoury of current penile
rehabilitation methods.
Implications for research
The very lowquality evidence indicatesmajormethodological lim-
itations of this body of evidence. These relate to standard method-
ological issues such as allocation concealment, blinding and com-
pleteness of follow-up. In addition, there were concerns about in-
consistency owing to clinical and methodological heterogeneity as
well as imprecision, due to inadequately powered studies. There-
fore, both for these comparisons and other rehabilitation strategies
there is a need for better quality research focused on patient-im-
portant outcomes. Rather than continued use in clinical practice
for which this review demonstrates no apparent benefit, the focus
might be placed on patient enrolment in meaningfully designed
clinical trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aydogdu 2011
Methods Study design: parallel RCT
Setting/country: single centre, Turkey
Dates when study was conducted: 2006-2008
Participants Inclusion criteria: aged < 65 years, preoperative full potency (IIEF-EF scores > 25 and
answered SEP question 2-3 ’yes’), no history of penile plaques or previous penile surgery,
clinical stage T1c or lower, PSA < 10 ng/mL and biopsy Gleason score < 8
Exclusion criteria: NR
Total number of participants randomly assigned: 74
Group A
• Number of participants randomly assigned: NR
• Mean age (years): 56.2
• Mean PSA (ng/mL): 6.3
• Gleason score (pathological): NA
• Tumour stage (pathological): NA
• IIEF-5: NR
• IIEF-EF: 26.2
Group B
• Number of participants randomly assigned: NR
• Mean age (years): 58.1
• Mean PSA (ng/mL): 5.8
• Gleason score (pathological): NA
• Tumour stage (pathological): NA
• IIEF-5: NR
• IIEF-EF: 26.5
Interventions Group A: tadalafil 20 mg/day, 3 days/week
Group B: no treatment
Surgery or cointervention: BNSRRP
Interval between surgery and intervention: 14-20 days
Intervention duration: 6 months
Washout period before outcome assessment: 5 months and 10-14 days
Total follow-up period: 12 months
Outcomes Primary outcomes
• EF
• Penile size
How measured: IIEF-EF Questionnaire, SEP question 2 and question 3, penile length
and circumference at both flaccid and at maximum erection
Time points measured: baseline, 3, 6 and 12 months
Time points reported: 3, 6 and 12 months
Secondary outcomes: NR
Safety outcomes: NR
Subgroup: none
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Aydogdu 2011 (Continued)
Funding sources NR
Declarations of interest NR
Notes Protocol:NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcomes not likely affected by
lack of blinding.
Incomplete outcome data (attrition bias)
Self-reported potency
Unclear risk 9/74 (12.1%) randomised participants not
included in analysis; group allocation un-
clear
Incomplete outcome data (attrition bias)
EF/IIEF
Unclear risk 9/74 (12.1%) randomised participants not
included in analysis; group allocation un-
clear
Incomplete outcome data (attrition bias)
Serious adverse event
Unclear risk No information given
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Unclear risk No information given
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
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Aydogdu 2011 (Continued)
Selective reporting (reporting bias) Unclear risk Predefined outcomes well described but
protocol not available
Other bias Low risk Not detected
Kim 2016
Methods Study design: randomised, double-blind, placebo-controlled trial
Setting/country: USA
Dates when study was conducted: 2006-2012
Participants Inclusion criteria: IIEF ≥ 21, nsRP
Exclusion criteria: known risk factors for ED, poor surgical candidates, health con-
ditions that are potential contraindications for PDE5I therapy, prior treatment with
PDE5I, and taking potent cytochrome P450 inhibitors or alpha-adrenergic blocking
agents (which could interact with sildenafil), or with known hypersensitivity to sildenafil
or other ingredients of Viagra
Total number of participants randomly assigned: 97
Group A
• Number of participants randomly assigned: 49
• Mean age (years): 54.3 (SD 7.1)
• Mean PSA (ng/mL): 5.1 (SD 2.9)
• Gleason score (pathological): 3 + 3: 35 (74.5%), 3 + 4: 6 (12.8%), 4 + 3: 3 (6.
4%), 4 + 4: 3 (6.4%)
• Tumour stage (pathological): T1c: 34 (72.3%), T2a-T2c: 12 (25.5%), T3: 1 (2.
1%)
• IIEF-5: NR
• Mean IIEF-EF: 28.0 (SD 4.6)
Group B
• Number of participants randomly assigned: 48
• Mean age (years): 54.3 (SD 7.1)
• Mean PSA (ng/mL): 4.2 (SD 2.8)
• Gleason score (pathological): 3 + 3: 39 (83.0%), 3 + 4: 5 (10.6%), 4 + 3: 0 (0.
0%), 4 + 4: 3 (6.4%)
• Tumour stage (pathological): T1c: 30 (63.8%), T2a-T2c: 16 (34.0%), T3: 1 (2.
1%)
• IIEF-5: NR
• Mean IIEF-EF: 28.3 (SD 5.5)
Interventions Group A: nightly PDE5I (sildenafil 50 mg)
Group B: placebo with 6 tablets of SC (100 mg) every 30 days for on-demand use
Surgery or cointervention: nsRP (RRP or RARP)
Interval between surgery and intervention: 1 day
Intervention duration: 12 months
Washout period before outcome assessment: 1 month
Total follow-up period: 13 months
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Kim 2016 (Continued)
Outcomes Primary outcomes
• Self-reported potency; IIEF-EF
How measured: Rigiscan device; IIEF-EF Questionnaire
Time points measured: 2 weeks, and then at 3, 6, 9 and 12 months
Time points reported: 2 weeks, and then at 3, 6, 9 and 12 months
Secondary outcomes: NR
Safety outcomes: NR
Subgroup: none
Funding sources Pfizer Inc.
Declarations of interest None reported
Notes Protocol:NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Treatment arm was concealed
from patients and clinical personnel un-
til all interventions and assessments were
complete.”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Quote: “Double-blind”
Judgement: not described who was
blinded.
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcomes were unlikely affected
by lack of blinding
Incomplete outcome data (attrition bias)
Self-reported potency
Low risk 2/49 (4.0%) participants in experimental
group and 1/48 (2.0%) participant in con-
trol group were not included in analysis
Incomplete outcome data (attrition bias)
EF/IIEF
Low risk 2/49 (4.0%) participants in experimental
group and 1/48 (2.0%) participant in con-
trol group were not included in analysis
Incomplete outcome data (attrition bias)
Serious adverse event
Unclear risk No information given
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Kim 2016 (Continued)
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants included in analysis
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk Predefined outcomes well described but
protocol not available
Other bias Low risk Not detected
McCullough 2010
Methods Study design: parallel, open-label, randomised-controlled trial
Setting/country: USA
Dates when study was conducted: NR
Participants Inclusion criteria: men < 70 years, sexually active in a stable relationship, with normal
EF as determined by the IIEF-EF domain score (IIEF-EF score ≥ 26 was required to be
eligible for study) and scheduled to undergo BNSRP
Exclusion criteria: men with Gleason score > 7, PSA > 20 ng/mL and postoperative
radiation therapy or androgen ablation
Total number of participants randomly assigned: 212
Group A
• Number of participants randomly assigned: 73
• Mean age (years): 55.6 (SD 5.9)
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Group B
• Number of participants randomly assigned: 139
• Mean age (years): 56.8 (SD 6.4)
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Interventions Group A: nightly SC 50 mg
Group B: intraurethral alprostadil 125 µg daily/at 2 month after surgery dose titration
250 µg
Surgery or cointervention: BNSRP
Interval between surgery and intervention: 1 month
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McCullough 2010 (Continued)
Intervention duration: 8 months
Washout period before outcome assessment: 1 month
Total follow-up period: 11 months
Outcomes Primary outcomes
• EDITS; IIEF; GAQ “Has the treatment you have been taking improved you
erection?,” SEP, SPL, adverse events
Howmeasured: EDITS; IIEF-EF; GAQ/SPL (SPL): measured from pubic bone to coro-
nal sulcus with a rigid ruler, adverse events as reported in study
Time points measured: EDITS: 11 months; other outcomes: 1, 9 and 11 months
Time points reported: EDITS: 11 months; other outcomes: 1, 9 and 11 months
Secondary outcome: none reported
Safety outcomes: adverse events
How measured: NR
Time point measured: postoperative 1, 9 and 11 months
Time point reported: postoperative 1, 9 and 11 months
Subgroup: none
Funding sources Vivus, Pfizer, Med Reviews, American Medical Systems, Auxilium, Coloplast, Cook,
GlaxoSmithKline/Schering Plough, Indevus, Johnson & Johnson, Medtronic, National
Institute ofHealth, Plethora, Sanofi-Aventis, Solvay, Theralogix, TimmMedical, Augusta
Medical, Watson, Aeterna-Zentaris, Steba-Pharma, Serenity and USOHIFU
Declarations of interest None reported
Notes Protocol: NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open label study”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “open label study”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcome not likely affected by
lack of blinding.
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Incomplete outcome data (attrition bias)
Self-reported potency
High risk 42/139 (30.2%)participants in experimen-
tal group and 14/73 (19.1%) participants
in control group not included in the anal-
ysis
Incomplete outcome data (attrition bias)
EF/IIEF
High risk 42/139 (30.2%)participants in experimen-
tal group and 14/73 (19.1%) participants
in control group not included in the anal-
ysis
Incomplete outcome data (attrition bias)
Serious adverse event
Unclear risk No information given
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Unclear risk No information given
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk Predefined outcomes well described but
protocol not available
Other bias Low risk Not detected
Montorsi 2008
Methods Study design: randomised, double-blind, double-dummy, multicentre, parallel group
trial
Setting/country: 87 centres across Europe, US, Canada and South Africa
Dates when study was conducted: December 2004 to September 2007
Participants Inclusion criteria: men, aged 18-64 years, in heterosexual relationship and scheduled
to undergo BNSRP surgery within approximately 1 month of screening; interest in
resuming sexual activity as soon as possible after surgery; normal preoperative EF (IIEF-
EF domain score ≥ 26 at screening without use of therapy or devices for improvement
of erections and no previous use of therapy or devices for ED; historical total PSA < 10
ng/mL; Gleason tumour score ≤ 7 on biopsy; no tumour perforation of the prostate
capsule
Exclusion criteria: men with residual prostate cancer or requirement for radiotherapy
or adjuvant therapy; need for further surgery due to haemorrhage; and urethral catheter
expected to be in place for ≥ 3 weeks due to anastomotic fistula; had contraindication
of PDE5I
Total number of participants randomly assigned: 628
Group A
• Number of participants randomly assigned: 210
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• Mean age (years): 57.4
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Group B
• Number of participants randomly assigned: 208
• Mean age (years): 56.8
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Group C
• Number of participants randomly assigned: 210
• Mean age (years): 57.1
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Interventions Group A: daily PDE5I: 10 mg nightly vardenafil (which could be decreased to 5 mg if
required) plus on-demand placebo)
Group B: on-demand PDE5i: flexible-dose (starting at 10 mg with the option to titrate
to 5 mg or 20 mg), on-demand vardenafil plus nightly placebo
Group C: nightly placebo, on-demand placebo
Surgery or cointervention: BNSRRP
Interval between surgery and intervention: 14 days
Intervention duration: 9 months
Washout period before outcome assessment: 2 months
Total follow-up period: 13.5 months
Outcomes Primary outcomes
• Percentage of men with an IIEF-EF score ≥ 22 (defined as mild ED)
How measured: IIEF-EF Questionnaire
Time points measured: at study endpoint after the 2-month washout period
Time points reported: at study endpoint after the 2-month washout period
Secondary outcomes
• Difference among treatment groups in the percentage of men with an IIEF-EF
score ≥ 22 at LOCF at the end of the DBT period and at the end of the open-label
period/IIEF-EF scores ≥ 17 and ≥ 26 at LOCF/SEP question 2 (“Were you able to
insert your penis into your partner’s vagina?”) and question 3 (“Did your erections last
long enough for you to have successful intercourse?”)
How measured: IIEF-EF Questionnaire/SEP Questionnaire
Time points measured: at the end of the DBT period and at the end of the open-label
period
Time points reported: at the end of the DBT period and at the end of the open-label
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period
Safety outcomes
How measured: adverse events
Time points measured: NR
Time points reported: NR
Subgroup: none
Funding sources Bayer Schering Pharma AG
Declarations of interest Professor Montorsi, Dr Brock, Dr Lee, and Professor Stief have acted as paid consultants
or investigators for Bayer Schering Pharma AG
Notes Protocol:NCT00492635
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation codes were com-
puter generated by Bayer Schering Pharma,
Germany.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Triple (Participant, Care Provider,
Investigator)” in the protocol
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Triple (Participant, Care Provider,
Investigator)” in the protocol
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcome not likely affected by
lack of blinding,
Incomplete outcome data (attrition bias)
Self-reported potency
High risk 94/210 (44.7%) participants in daily var-
denafil group, 73/208 (35.0%)participants
in on-demand vardenafil group and 4/210
(39.5%)participants in placebo groupwere
not included in the analysis
Incomplete outcome data (attrition bias)
EF/IIEF
High risk 67/210 (31.9%) participants in daily var-
denafil group, 59/208 (28.3%)participants
in on-demand vardenafil group and57/210
(27.1%)participants in placebo groupwere
not included in the analysis
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Incomplete outcome data (attrition bias)
Serious adverse event
Low risk 3/210 (1.4%) participants in daily varde-
nafil group, 4/208 (1.9%) participants in
on-demand vardenafil group and 4/210 (1.
9%) participants in placebo group were not
included in the analysis
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Low risk Protocol was published and prespecified
study outcomes were analysed as planned
Other bias Low risk Not detected
Montorsi 2014
Methods Study design: randomised double-blind placebo-controlled trial
Setting/country: 50 centres from 9 European countries and Canada
Dates when study was conducted: November 2009 to August 2011
Participants Inclusion criteria: men aged < 68 years at the time of nsRP with normal preoperative
EF who underwent nsRP for organ-confined, non-metastatic prostate cancer (Gleason
score ≤ 7, PSA < 10 ng/mL). Postsurgical inclusion criteria included the development
of ED, as measured by a participant-reported Residual Erection Function score of ≤ 3
(“penis is hard enough for penetration but not completely hard”)
Exclusion criteria: men with no history of ED, who had received previous or current
treatment with tadalafil or any other PDE5I; had undergone, or planned to undergo,
radiation or hormonal therapy for prostate cancer; history of prostatic surgery or pro-
static physical treatments; history of diabetes mellitus; history of galactose intolerance,
lapp lactase deficiency or glucose-galactose malabsorption; clinically significant renal in-
sufficiency as determined by the investigator
Total number of participants randomly assigned: 423
Group A
• Number of participants randomly assigned: 139
• Mean age (years): 58.6 (SD 5.07)
• PSA: NA
• Gleason score (pathological): NA
• Tumour stage (pathological): NA
• IIEF-5:
• Mean IIEF-EF: 6.0 (SD 5.8)
Group B
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• Number of participants randomly assigned: 143
• Mean age (years): 57.5 (SD 5.91)
• PSA: NA
• Gleason score (pathological): NA
• Tumour stage (pathological): NA
• IIEF-5: NR
• Mean IIEF-EF: 6.7 (SD 5.57)
Group C
• Number of participants randomly assigned: 141
• Mean age (years): 57.6 (SD 5.69)
• PSA: NA
• Gleason score (pathological): NA
• Tumour stage (pathological): NA
• IIEF-5: NR
• Mean IIEF-EF: 6.5 (SD 6.08)
Interventions Group A: tadalafil 5 mg once daily
Group B: on-demand tadalafil 20 mg
Group C: placebo
Surgery or cointervention: bilateral nerve-sparing surgery during screening period
Interval between surgery and intervention: NR
Intervention duration: 9 months
Washout period before outcome assessment: 6 weeks (washout) followed by 3months’
open label
Total follow-up period: 13.5 months (after 3 months’ open label)
Outcomes Primary outcomes
• Unassisted EF
How measured: proportion of men achieving an IIEF-EF score ≥ 22
Time points measured: at end of DFW
Time points reported: at end of DFW (primary outcome)
Secondary outcomes
• Montorsi 2014 publication: change from baseline in IIEF and SEP, penile length
• Moncada 2015 publication: time to EF-recovery, ED severity, improvement,
maintenance of treatment response
Howmeasured: Montorsi 2014: IIEF and SEPQuestionnaire: measurements were taken
before administration of any sedatives or anaesthetics
Moncada 2015: defined as the time from baseline to reach an IIEF-EF ≥ 22 during
DBT
IIEF-EF scores were categorised into the following ED severity categories: severe (0-
10), moderate (11-16), mild (17-25) and normal (26-30). ED severity was assessed at
baseline, end of DBT, and end of DFW. Improvement was defined as an IIEF-EF score
of ≥ 1 category higher than baseline (or maintaining normal EF) at the end of DBT.
Maintenance of treatment response, assessed for participants who improved≥ 1 category
after DBT, was defined as either maintaining this improved category until the end of
DFW or declining after DBT but still maintaining a higher category at the end of DFW
than at baseline
Time points measured: Montorsi 2014 (at 9, 10.5 and 13 months, before RP and 9
months (after DBT))/Moncada 2015 (time to event: at baseline, end of DBT and end
48Penile rehabilitation for postprostatectomy erectile dysfunction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Montorsi 2014 (Continued)
of DFW; at the end of DBT; at baseline, DBT and DFW)
Time points reported: Montorsi 2014 (at 9, 10.5 and 13 months, before RP and 9
months (after DBT))/Moncada 2015 (time to event: at baseline, end of DBT and end
of DFW; at the end of DBT; at baseline, DBT and DFW)
Safety outcomes
How measured: adverse events
Time points measured: after DBT
Time points reported: after DBT
Subgroup: none
Funding sources Eli Lilly
Declarations of interest I Moncada has been a consultant for, and received speaker honoraria and travel expenses
from, Eli Lilly. C Henneges, C Turbi and H Buettner are employees of Eli Lilly and
Company and own Eli Lilly stock. FR de Bethencourt, E Lledó-García, JI Martinez-
Salamanca and J Romero-Otero have no conflicts of interest to disclose
Notes Protocol:NCT01026818
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Quote: “interactive voice response system
and stratified by age group and country.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Matching placebo tablets identi-
cal to the 5-mg and 20-mg tadalafil tablets
were used to ensure that the blinded regi-
men was identical.”
Judgement: “Double-blind (Participants
and investigator)” in protocol and “placebo
controlled” in article
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Matching placebo tablets identi-
cal to the 5-mg and 20-mg tadalafil tablets
were used to ensure that the blinded regi-
men was identical.”
Judgement: “Double-blind (Participants
and investigator)” in protocol and “placebo
controlled” in article
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcome not likely affected by
lack of blinding.
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Incomplete outcome data (attrition bias)
Self-reported potency
Low risk All participants were included in the anal-
ysis except 1 participant in tadalafil on-de-
mand group
Incomplete outcome data (attrition bias)
EF/IIEF
Low risk All participants were included in the anal-
ysis except 1 participant in tadalafil on-de-
mand group
Incomplete outcome data (attrition bias)
Serious adverse event
Unclear risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Sexual quality of life
Low risk All participants were included in the anal-
ysis except 1 participant in tadalafil on-de-
mand group
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk While protocol was published, a few pre-
defined outcomes in protocol were not re-
ported in article
Other bias Low risk Not detected
Pace 2010
Methods Study design: RCT
Setting/country: Italy
Dates when study was conducted: 2005-2009
Participants Inclusion criteria: men with total PSA 510 ng/mL, Gleason score ≤ 7 on biopsy, no
capsular involvement, normal preoperative EF assessed by an IIEF score ≥ 26, without
the use of any therapy for improving erection
Exclusion criteria:menwith cardiovascular diseases and previous pharmacological treat-
ments which did not allow the contemporary use of PDE5I
Total number of participants randomly assigned: 40
Group A
• Number of participants randomly assigned: 20
• Age: NR
• Mean PSA (ng/mL): 5.5 (range 1.2-9.9)
• Gleason score (pathological): 6: 18 (90.0%)/ 7: 2 (10.0%)
• Tumour stage (pathological): T1b and T1c: 10 (50.0%), T2a: 9 (45.0%), T2b: 1
(5.0%)
• IIEF-5: NR
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• Mean IIEF-EF: 26.2
Group B
• Number of participants randomly assigned: 20
• Age (years): NR
• PSA (ng/mL): 6 (range 1.8-8.9)
• Gleason score (pathological): 6: 18 (90.0%)/ 7: 2 (10.0%)
• Tumour stage (pathological): T1b and T1c: 9 (45.0%), T2a: 9 (45.0%), T2b: 2
(10.0%)
• IIEF-5: NR
• Mean IIEF-EF: 26.5
Interventions Group A: sildenafil 50 mg or 100 mg at night
Group B: no treatment
Surgery or cointervention: BNSRRP
Interval between surgery and intervention: 2 weeks
Intervention duration: 8 weeks
Washout period before outcome assessment: 14 weeks
Total follow-up period: 24 weeks
Outcomes Primary outcomes
• IIEF; potency rates; percentage of men who were capable of having medication-
unassisted intercourse; percentage of men with normal EF domain; satisfaction rate
How measured: NR (maybe IIEF-EF); NR; NR; IIEF-EF; NR
Time points measured: before surgery and then at 3, 6, 12 and 24 weeks after NSRP;
NR; NR; before surgery and then at 3, 6, 12 and 24 weeks after NSRP; NR
Time points reported: before surgery and then at 3, 6, 12 and 24 weeks after NSRP;
before and at 24 weeks; before and at 24 weeks; before and at 24 weeks; before and at
24 weeks
Secondary outcomes
• Rates of treatment discontinuation
How measured: NR
Time points measured: 8 weeks
Time points reported: 8 weeks
Safety outcomes
How measured: adverse events
Time points measured: NR
Time points reported: NR
Subgroup: none
Funding sources NR
Declarations of interest NR
Notes Protocol:NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcome not likely affected by
lack of blinding.
Incomplete outcome data (attrition bias)
Self-reported potency
Unclear risk Not available
Incomplete outcome data (attrition bias)
EF/IIEF
Unclear risk Not available
Incomplete outcome data (attrition bias)
Serious adverse event
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk Predefined outcomes well described but
protocol was not available
Other bias Low risk Not detected
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Methods Study design: randomised, double-blind, placebo-controlled trial
Setting/country: 16 sites in North America, France, Belgium and Australia screened
participants and 11 sites in North America and France
Dates when study was conducted: April 1999 to October 2001
Participants Inclusion criteria:men aged 18-70 years; weighing 50-125 kg with normal preoperative
EF (combined score of at least 8 on question 3 and question 4 of IIEF); wish to return
to sexual activity after surgery and be in a stable, heterosexual relationship for the past 6
months
Exclusion criteria: pathological stage > pT2; tumour Gleason score≥ 8 on preoperative
biopsy; PSA ≥ 20 mg/L; positive lymph nodes or required postoperative radiation or
androgen ablation therapy; had a sleep disorder; were taking sedative/hypnotics as sleep
aids or receiving nitrates or any treatment for ED
Total number of participants randomly assigned: 125
Group A
• Number of participants randomly assigned: 41
• Mean age (years): 55 (SD 6)
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Group B
• Number of participants randomly assigned: 40
• Mean age (years): 55 (SD 6)
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Group C
• Number of participants randomly assigned: 42
• Mean age (years): 57 (SD 7)
• PSA: NR
• Gleason score (pathological): NR
• Tumour stage (pathological): NR
• IIEF-5: NR
• IIEF-EF: NR
Interventions Group A: sildenafil 100 mg once daily night-time
Group B: sildenafil 50 mg once daily night-time
Group C: placebo once daily night-time
Surgery or cointervention: BNSRRP by experienced surgeons
Interval between surgery and intervention: 4 weeks
Intervention duration: 36 weeks’ double-blind study period
Washout period before outcome assessment: 8 weeks
Total follow-up period: 48 weeks
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Outcomes Primary outcomes
• Percentage of men who were responders
How measured: stringent responder definition was established a priori as those partic-
ipants who, at the end of phase 3, had a combined score of ≥ 8 for question 3 and
question 4 of the IIEF, and also answered ’yes’ to the question, “Over the past 4 weeks,
have your erections been good enough for satisfactory sexual activity?”
Time points measured: at 44 weeks of treatment (36 weeks’ double blind + 8 weeks
washout; 48 weeks after surgery)
Time points reported: at 44 weeks of treatment (36 weeks’ double blind + 8 weeks
washout; 48 weeks after surgery)
Secondary outcomes
• Changes from baseline in the 6-item Erectile Function domain of the IIEF;
duration of penile tumescence and rigidity
How measured: IIEF-EF Questionnaire; plethysmography
Time points measured: baseline, 12, 24 and 36 weeks after treatment (double blinded;
for 40 weeks after surgery), 44 weeks after treatment (additional 8 weeks’ washout; 48
weeks after surgery)
Time points reported: before and at 44 weeks of treatment (36 weeks double blinded+
8 weeks washout; 48 weeks after surgery)
Safety outcomes
How measured: adverse events
Time points measured: NR
Time points reported: NR
Subgroup: none
Funding sources Pfizer Inc
Declarations of interest R Siegel was an employee of Pfizer at the time of this research
Gerald Brock: consultant, investigator for clinical research, and speakers bureau member
for Pfizer Inc, Lilly-ICOS, Bayer, GSK, Johnson & Johnson, Coloplast and AMS
Francois Giuliano: investigator for clinical and preclinical research, meeting lecturer and
member of advisory board for Pfizer Inc, Bayer-GSK, Lilly-ICOS, Johnson & Johnson;
preclinical research for Solvay Pharmaceuticals, Roche; investigator for preclinical re-
search and meeting lecturer for Sanofi-Aventis
Larry Levine: Consultant for Pfizer Inc, Lilly-ICOS, Auxillium, Johnson & Johnson;
investigator for clinical research for Pfizer Inc, Bayer-GSK, Auxillium; lecturer for Pfizer
Inc, Lilly-ICOS, Schering-Plough
Larry Lipshultz: Consultant for Pfizer Inc, Lilly-ICOS, Auxillium, and Solvay Pharma-
ceuticals; investigator for clinical research for Pfizer Inc and Lilly-ICOS
Andrew McCullough: Consultant for Pfizer Inc, Lilly-ICOS, Auxillium, Johnson &
Johnson; investigator for clinical research for Pfizer Inc, Lilly-ICOS, Bayer-GSK, Guil-
ford Pharmaceuticals, Ion Channel, Johnson & Johnson and Schering Plough; advisory
board and lecturer for Pfizer Inc, Lilly-ICOS and Auxillium
Francesco Montorsi: Consultant for American Medical System, Bayer-GSK, Johnson &
Johnson, Lilly ICOS, Pfizer Inc and Takeda
Harin Padma-Nathan: Consultant, received grant support (for this and other clinical
trials) from, and participated in CME educational program for Pfizer Inc, Lilly-ICOS,
Bayer-GSK, NexMed and Palatin Technologies
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Notes Protocol:NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated randomisa-
tion was in a 1:1:1 ratio using the method
of random permuted blocks and a pseudo-
random number generator.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blind, placebo
controlled”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Double-blind, placebo
controlled”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcome are not likely affected
by lack of blinding
Incomplete outcome data (attrition bias)
Self-reported potency
High risk 13/41 (31.7%) participants in sildenafil
100 mg group, 17/40 (42.5%) participants
in sildenafil 50 mg group and 17/42 (40.
4%) participants in placebo group were not
included in the analysis
Incomplete outcome data (attrition bias)
EF/IIEF
High risk 13/41 (31.7%) participants in sildenafil
100 mg group, 17/40 (42.5%) participants
in sildenafil 50 mg group and 17/42 (40.
4%) participants in placebo group were not
included in the analysis
Incomplete outcome data (attrition bias)
Serious adverse event
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk No information given
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants were included in the anal-
ysis.
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Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk Predefined outcomes were well described
but protocol was not available
Other bias High risk Premature termination due to lack of ef-
ficacy of intervention. Statistical method
change during study
Pavlovich 2013
Methods Study design: randomised double-blind, placebo-controlled trial
Setting/country: single institution in USA
Dates when study was conducted: 2006-2007
Participants Inclusion criteria: men choosing to undergo nsRP who satisfied the following criteria:
aged < 65 years, untreated prostate cancer < cT2b, biopsy Gleason score < 8, baseline
IIEF-EF score ≥ 25/30, no PDE5I use and presence of a steady sexual partner
Exclusion criteria: NR
Total number of participants randomly assigned: 100
Group A
• Number of participants randomly assigned: 50
• Mean age (years): 54.3 (range 42-63)
• Mean PSA (ng/mL): 4.7 (range 0.6-14)
• Gleason score (pathological): 6: 41 (82.0%); 7: 9 (18.0%)
• Tumour stage (pathological): T1c: 37 (74.0%); T2a: 13 (26.0%)
• IIEF-5: NR
• Mean IIEF-EF: 29.4 (range 26-30)
Group B
• Number of participants randomly assigned: 50
• Mean age (years): 53.6 (range 40-64)
• Mean PSA (ng/mL): 5.1 (range 0.8-9.0)
• Gleason score (pathological): 6: 42 (84.0%); 7: 8 (16.0%)
• Tumour stage (pathological): T1c: 40 (80.0%); T2a: 10 (20.0%)
• IIEF-5: NR
• Mean IIEF-EF: 29.3 (range 26-30)
Interventions Group A: nightly sildenafil 50 mg with on-demand placebo
GroupB: on-demand sildenafil 50mg (maximum6 tablets/month) with nightly placebo
Surgery or cointervention: nerve-sparing minimally invasive RP (either laparoscopic
or RARP)
Interval between surgery and intervention: 1 day
Intervention duration: 1 year double-blind study period
Washout period before outcome assessment: 4 weeks
Total follow-up period: 13 months
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Outcomes Primary outcomes
• EF recovery/ IIEF-EF score
How measured: IIEF-EF Questionnaire (not defined)
Time points measured: baseline, at 1, 3, 6, 9, 12 and 13 months
Time points reported: baseline, at 1, 3, 6, 9, 12 and 13 months
Secondary outcomes
• EPIC Sexual Function Subscale and EPIC Sexual Bother Subscale scores, and
specific items of the IIEF (2, 6 and 15, and EPIC Questionnaire (57, 59 and 63)
concerning erectile confidence, quality and intercourse frequency
How measured: EPIC Questionnaire and IIEF
Time points measured: baseline, at 1, 3, 6, 9, 12 and 13 months
Time points reported: baseline, at 1, 3, 6, 9, 12 and 13 months
Safety outcomes
How measured: adverse events
Time points measured: NR
Time points reported: NR
Subgroup: none
Funding sources None (acknowledgement: this trial was supported with an independent investigator-
initiated grant from Pfizer Pharmaceuticals)
Declarations of interest None
Notes Protocol: NA
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blind, placebo
controlled”
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “Double-blind, placebo
controlled”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Objective outcomes not likely affected by
lack of blinding.
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Incomplete outcome data (attrition bias)
Self-reported potency
High risk Short term: 16/50 (32.0%) participants in
daily group and 20/50 (40.0%) partici-
pants in on-demand group were not in-
cluded in the analysis
Long term: 14/50 (28.0%) participants in
daily group and 12/50 (24.0%) partici-
pants in on-demand group were not in-
cluded in the analysis
Incomplete outcome data (attrition bias)
EF/IIEF
High risk Short term: 16/50 (32.0%) participants in
daily group and 20/50 (40.0%) partici-
pants in on-demand group were not in-
cluded in the analysis
Long term: 14/50 (28.0%) participants in
daily group and 12/50 (24.0%) partici-
pants in on-demand group were not in-
cluded in the analysis
Incomplete outcome data (attrition bias)
Serious adverse event
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Sexual quality of life
Unclear risk Quote: “None differed significantly be-
tween treatment groups”
Judgement: no available data
Incomplete outcome data (attrition bias)
Treatment discontinuation
Low risk All participants were included in the anal-
ysis.
Incomplete outcome data (attrition bias)
Acceptability of the intervention
Unclear risk No information given
Selective reporting (reporting bias) Unclear risk Predefined outcomes are well described but
protocol was not available
Other bias Low risk Not detected
BNSRP: bilateral nerve-sparing radical retropubic prostatectomy; BNSRRP: bilateral nerve-sparing radical retropubic prostatectomy;
DBT: double-blind treatment; DFW: drug-free washout; ED: erectile dysfunction; EDITS: Erectile Dysfunction Inventory of
Treatment Satisfaction; EF: erectile function; GAQ: Global Assessment Question; IIEF: International Index of Erectile Function;
IIEF-EF: International Index of Erectile Function - Erectile Function domain; LOCF: last observation carried forward; PSA: prostate-
specific antigen; NA: not applicable; NR: not reported; nsRP: nerve-sparing radical prostatectomy; PDE5I: phosphodiesterase
5 inhibitor; RARP: robot-assisted radical prostatectomy; RCT: randomised controlled trial; RP: retropubic prostatectomy; RRP:
radical retropubic prostatectomy; SC: sildenafil citrate; SD: standard deviation; SEP: Sexual Encounter Profile; SPL: stretched penile
length.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bannowsky 2008 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Bannowsky 2010 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Bannowsky 2012 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Brock 2003 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Canat 2015 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Cavallini 2005 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Chambers 2015 Wrong intervention
Engel 2011 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Fode 2014 Wrong intervention
Kim 2017 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Kohler 2007 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Kosev 2013 Wrong study design
McCullough 2008 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Montorsi 1997 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Montorsi 2004 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Mulhall 2013 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Naccarato 2016 Inappropriate assessment of outcomes (not fair comparison at the time of outcome assessment)
Nehra 2005 Inappropriate assessment of outcome (not fair comparison at the time of outcome assessment)
Raina 2007 Wrong study design
Seo 2014 Wrong study design (retrospective study)
Yassin 2010 Incorrect reference
59Penile rehabilitation for postprostatectomy erectile dysfunction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self-reported potency (short
term)
4 628 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.91, 1.41]
2 Erectile function (short term) 5 757 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.80, 1.55]
3 Serious adverse event (short
term)
3 443 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.11, 0.94]
4 Treatment discontinuation
(short term)
3 443 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.72, 1.34]
5 International Index of Erectile
Function - Erectile Function
domain (IIEF-EF) (short term)
2 356 Mean Difference (IV, Random, 95% CI) 2.09 [-1.85, 6.03]
6 Sexual quality of life (long term) 1 280 Mean Difference (IV, Random, 95% CI) 3.20 [-5.91, 12.31]
7 Treatment discontinuation (long
term)
1 420 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.85, 1.48]
Comparison 2. Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self-reported potency (short
term)
2 532 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.62, 1.53]
2 Erectile function (short term) 2 573 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.65, 1.55]
3 Serious adverse event (short
term)
1 282 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 4.04]
4 Treatment discontinuation
(short term)
1 282 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.85, 2.12]
5 International Index of Erectile
Function - Erectile Function
domain (IIEF-EF) (short term)
1 281 Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.15, 0.47]
6 Self-reported potency (long
term)
1 94 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.60, 1.67]
7 Erectile function (long term) 2 168 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.14]
8 Serious adverse event (long term) 1 100 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 71.92]
9 Sexual quality of life (long term) 1 281 Mean Difference (IV, Random, 95% CI) 4.0 [-4.84, 12.84]
10 Treatment discontinuation
(long term)
3 612 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.86, 1.38]
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Comparison 3. Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral prostaglandin (IUP) E1
(short term)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self-reported potency 1 156 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.79, 1.52]
2 Erectile function (International
Index of Erectile Function
- Erectile Function domain
(IIEF-EF) > 26)
1 156 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.84, 3.20]
3 Erectile function (IIEF-EF > 17) 1 156 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.79, 1.81]
Analysis 1.1. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 1 Self-reported potency (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 1 Self-reported potency (short term)
Study or subgroup Scheduled Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aydogdu 2011 26/32 22/33 32.3 % 1.22 [ 0.91, 1.63 ]
Montorsi 2008 37/116 44/127 25.2 % 0.92 [ 0.64, 1.32 ]
Montorsi 2014 39/139 40/141 23.7 % 0.99 [ 0.68, 1.44 ]
Pace 2010 17/20 11/20 18.9 % 1.55 [ 1.00, 2.39 ]
Total (95% CI) 307 321 100.0 % 1.13 [ 0.91, 1.41 ]
Total events: 119 (Scheduled), 117 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.45, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours scheduled
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Analysis 1.2. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 2 Erectile function (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 2 Erectile function (short term)
Study or subgroup Scheduled Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aydogdu 2011 21/32 19/33 32.4 % 1.14 [ 0.78, 1.68 ]
Montorsi 2008 34/143 44/153 32.4 % 0.83 [ 0.56, 1.22 ]
Montorsi 2014 29/139 26/141 26.3 % 1.13 [ 0.70, 1.82 ]
Pace 2010 6/20 3/20 6.3 % 2.00 [ 0.58, 6.91 ]
Padma-Nathan 2008 14/51 1/25 2.6 % 6.86 [ 0.96, 49.29 ]
Total (95% CI) 385 372 100.0 % 1.11 [ 0.80, 1.55 ]
Total events: 104 (Scheduled), 93 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.39, df = 4 (P = 0.17); I2 =37%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours scheduled
62Penile rehabilitation for postprostatectomy erectile dysfunction (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 3 Serious adverse event (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 3 Serious adverse event (short term)
Study or subgroup Scheduled Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2014 2/139 10/141 51.8 % 0.20 [ 0.05, 0.91 ]
Pace 2010 0/20 0/20 Not estimable
Padma-Nathan 2008 3/81 3/42 48.2 % 0.52 [ 0.11, 2.46 ]
Total (95% CI) 240 203 100.0 % 0.32 [ 0.11, 0.94 ]
Total events: 5 (Scheduled), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours scheduled Favours placebo
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Analysis 1.4. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 4 Treatment discontinuation (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 4 Treatment discontinuation (short term)
Study or subgroup Scheduled Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2014 34/139 33/141 55.2 % 1.05 [ 0.69, 1.59 ]
Pace 2010 0/20 0/20 Not estimable
Padma-Nathan 2008 30/81 17/42 44.8 % 0.92 [ 0.58, 1.46 ]
Total (95% CI) 240 203 100.0 % 0.98 [ 0.72, 1.34 ]
Total events: 64 (Scheduled), 50 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours scheduled Favours placebo
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Analysis 1.5. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 5 International Index of Erectile Function - Erectile Function domain (IIEF-EF) (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 5 International Index of Erectile Function Erectile Function domain (IIEF-EF) (short term)
Study or subgroup Scheduled Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montorsi 2014 139 6.24 (12.04) 141 5.98 (12.37) 54.8 % 0.26 [ -2.60, 3.12 ]
Padma-Nathan 2008 51 13.1 (9.4) 25 8.8 (7) 45.2 % 4.30 [ 0.53, 8.07 ]
Total (95% CI) 190 166 100.0 % 2.09 [ -1.85, 6.03 ]
Heterogeneity: Tau2 = 5.25; Chi2 = 2.80, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours scheduled
Analysis 1.6. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 6 Sexual quality of life (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 6 Sexual quality of life (long term)
Study or subgroup Scheduled Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montorsi 2014 139 36.6 (39.35) 141 33.4 (38.43) 100.0 % 3.20 [ -5.91, 12.31 ]
Total (95% CI) 139 141 100.0 % 3.20 [ -5.91, 12.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours scheduled
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Analysis 1.7. Comparison 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment,
Outcome 7 Treatment discontinuation (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 1 Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment
Outcome: 7 Treatment discontinuation (long term)
Study or subgroup Scheduled Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2008 73/210 65/210 100.0 % 1.12 [ 0.85, 1.48 ]
Total (95% CI) 210 210 100.0 % 1.12 [ 0.85, 1.48 ]
Total events: 73 (Scheduled), 65 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours scheduled Favours placebo
Analysis 2.1. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 1 Self-reported potency (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 1 Self-reported potency (short term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2008 37/116 55/135 53.1 % 0.78 [ 0.56, 1.09 ]
Montorsi 2014 39/139 32/142 46.9 % 1.25 [ 0.83, 1.87 ]
Total (95% CI) 255 277 100.0 % 0.97 [ 0.62, 1.53 ]
Total events: 76 (Daily), 87 (On-demand)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours on-demand Favours daily
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Analysis 2.2. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 2 Erectile function (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 2 Erectile function (short term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2008 34/143 43/149 56.2 % 0.82 [ 0.56, 1.21 ]
Montorsi 2014 29/139 23/142 43.8 % 1.29 [ 0.79, 2.11 ]
Total (95% CI) 282 291 100.0 % 1.00 [ 0.65, 1.55 ]
Total events: 63 (Daily), 66 (On-demand)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours on demand Favours daily
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Analysis 2.3. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 3 Serious adverse event (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 3 Serious adverse event (short term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2014 2/139 3/143 100.0 % 0.69 [ 0.12, 4.04 ]
Total (95% CI) 139 143 100.0 % 0.69 [ 0.12, 4.04 ]
Total events: 2 (Daily), 3 (On-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily Favours on-demand
Analysis 2.4. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 4 Treatment discontinuation (short term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 4 Treatment discontinuation (short term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Montorsi 2014 34/139 26/143 100.0 % 1.35 [ 0.85, 2.12 ]
Total (95% CI) 139 143 100.0 % 1.35 [ 0.85, 2.12 ]
Total events: 34 (Daily), 26 (On-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily Favours on-demand
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Analysis 2.5. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 5 International Index of Erectile Function - Erectile Function domain (IIEF-EF) (short
term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 5 International Index of Erectile Function Erectile Function domain (IIEF-EF) (short term)
Study or subgroup Daily On-demand
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Montorsi 2014 139 2.54 (1.37) 142 2.38 (1.26) 100.0 % 0.16 [ -0.15, 0.47 ]
Total (95% CI) 139 142 100.0 % 0.16 [ -0.15, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours on-demand Favours daily
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Analysis 2.6. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 6 Self-reported potency (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 6 Self-reported potency (long term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kim 2016 18/47 18/47 100.0 % 1.00 [ 0.60, 1.67 ]
Total (95% CI) 47 47 100.0 % 1.00 [ 0.60, 1.67 ]
Total events: 18 (Daily), 18 (On-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours on-demand Favours daily
Analysis 2.7. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 7 Erectile function (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 7 Erectile function (long term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kim 2016 13/47 15/47 47.8 % 0.87 [ 0.46, 1.62 ]
Pavlovich 2013 11/36 18/38 52.2 % 0.65 [ 0.36, 1.17 ]
Total (95% CI) 83 85 100.0 % 0.74 [ 0.48, 1.14 ]
Total events: 24 (Daily), 33 (On-demand)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours on-demand Favours daily
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Analysis 2.8. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 8 Serious adverse event (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 8 Serious adverse event (long term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pavlovich 2013 1/50 0/50 100.0 % 3.00 [ 0.13, 71.92 ]
Total (95% CI) 50 50 100.0 % 3.00 [ 0.13, 71.92 ]
Total events: 1 (Daily), 0 (On-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily Favours on-demand
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Analysis 2.9. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 9 Sexual quality of life (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 9 Sexual quality of life (long term)
Study or subgroup Daily On-demand
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montorsi 2014 139 36.6 (39.35) 142 32.6 (36.16) 100.0 % 4.00 [ -4.84, 12.84 ]
Total (95% CI) 139 142 100.0 % 4.00 [ -4.84, 12.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours on demand Favours daily
Analysis 2.10. Comparison 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5
inhibitor, Outcome 10 Treatment discontinuation (long term).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 2 Daily phosphodiesterase 5 inhibitor versus on-demand phosphodiesterase 5 inhibitor
Outcome: 10 Treatment discontinuation (long term)
Study or subgroup Daily On-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kim 2016 12/47 11/47 11.0 % 1.09 [ 0.54, 2.22 ]
Montorsi 2008 73/210 67/208 76.3 % 1.08 [ 0.82, 1.41 ]
Pavlovich 2013 14/50 12/50 12.7 % 1.17 [ 0.60, 2.27 ]
Total (95% CI) 307 305 100.0 % 1.09 [ 0.86, 1.38 ]
Total events: 99 (Daily), 90 (On-demand)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily Favours on-demand
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Analysis 3.1. Comparison 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral
prostaglandin (IUP) E1 (short term), Outcome 1 Self-reported potency.
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral prostaglandin (IUP) E1 (short term)
Outcome: 1 Self-reported potency
Study or subgroup PDE5I IUP Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
McCullough 2010 30/59 45/97 100.0 % 1.10 [ 0.79, 1.52 ]
Total (95% CI) 59 97 100.0 % 1.10 [ 0.79, 1.52 ]
Total events: 30 (PDE5I), 45 (IUP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily IUP Favours daily PDE5I
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Analysis 3.2. Comparison 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral
prostaglandin (IUP) E1 (short term), Outcome 2 Erectile function (International Index of Erectile Function -
Erectile Function domain (IIEF-EF) > 26).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral prostaglandin (IUP) E1 (short term)
Outcome: 2 Erectile function (International Index of Erectile Function Erectile Function domain (IIEF-EF) > 26)
Study or subgroup PDE5I IUP Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
McCullough 2010 14/59 14/97 100.0 % 1.64 [ 0.84, 3.20 ]
Total (95% CI) 59 97 100.0 % 1.64 [ 0.84, 3.20 ]
Total events: 14 (PDE5I), 14 (IUP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily IUP Favours daily PDE5I
Analysis 3.3. Comparison 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral
prostaglandin (IUP) E1 (short term), Outcome 3 Erectile function (IIEF-EF > 17).
Review: Penile rehabilitation for postprostatectomy erectile dysfunction
Comparison: 3 Daily phosphodiesterase 5 inhibitor (PDE5I) versus daily intraurethral prostaglandin (IUP) E1 (short term)
Outcome: 3 Erectile function (IIEF-EF > 17)
Study or subgroup PDE5I IUP Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
McCullough 2010 24/59 33/97 100.0 % 1.20 [ 0.79, 1.81 ]
Total (95% CI) 59 97 100.0 % 1.20 [ 0.79, 1.81 ]
Total events: 24 (PDE5I), 33 (IUP)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours daily IUP Favours daily PDE5I
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A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics
Study Trial
period
Setting/
country
Descrip-
tion
of partici-
pants
Interven-
tion(s)
and com-
parator(s)
Duration
of inter-
vention,
washout
and to-
tal follow-
upa
Mean age
(SD)
Mean PSA
(SD)
Patholog-
ical Glea-
son score
n (%)
Patho-
logical tu-
mour
stage n
(%)
Aydogdu
2011
2006-
2008
Single in-
stitution/
Turkey
Men aged
< 65 years,
preoper-
ative full
potency
(IIEF-EF
scores >
25 and
answered
SEP ques-
tions 2-
3 ’yes’),
no history
of penile
plaques or
previous
penile
surgery,
clinical
stage T1c
or lower,
PSA < 10
ng/mL and
a biopsy
Gleason
score < 8
No exclu-
sion
criteria re-
ported
Tadalafil
20 mg/day,
3 days/
week
Inter-
vention: 6
months
Washout:
5 months
and 10-14
days
Follow-up:
12 months
56.2 6.3 NR NR
No
treatment
58.1 5.8 NR NR
Kim 2016 2006-
2012
Sin-
gle institu-
tion/USA
Men with
localised
prostate
cancerwho
Nightly
sildenafil
50 mg +
6 tablets of
Interven-
tion: 12
months
Washout:
54.3 (7.1) 5.1 (2.9) 3+3: 35
(74.5)
3+4: 6 (12.
T1c: 34
(72.3)
T2a-T2c:
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Table 1. Baseline characteristics (Continued)
elected to
go surgical
treatment.
These men
had nor-
mal preop-
erative EF,
defined as
Sexual
Health In-
dex for
Men score
≥ 21 and
at
> 1 erectile
event with
tip pe-
nile rigid-
ity > 60%
and lasting
> 10 min-
utes in du-
ration doc-
u-
mented by
Rigiscan
Men with
known risk
factors for
ED and
men with
health
conditions
which are
potential
con-
traindica-
tions for
PDE5I
therapy
were
excluded
from
study. Men
taking
potent cy-
tochrome
sildenafil
100mgper
month for
on-de-
mand use
1 month
Follow-up:
13 months
8)
4+3: 3 (6.
4)
4+4: 3 (6.
4)
12 (25.5)
T3:1 (2.1)
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Table 1. Baseline characteristics (Continued)
P450
inhibitors
or alpha-
adrenergic
blocking
agents
(which
could in-
teract with
sildenafil)
, or with
known
hypersen-
sitivity to
sildenafil
or other
ingredients
of Viagra
were also
excluded
Matched
placebo +
6 tablets of
sildenafil
100mgper
month for
on-de-
mand use
53.7 (7.1) 4.2 (2.8) 3+3: 39
(83.0)
3+4: 5 (10.
6)
4+3: 0 (0.
0)
4+4: 3 (6.
4)
T1c: 30
(63.8)
T2a-T2c:
16 (34.0)
T3: 1 (2.1)
McCul-
lough
2010
NA Multicen-
tre/USA
Men aged
< 70 years,
sexually ac-
tive in a
stable rela-
tion-
ship, with
normal EF
as deter-
mined by
IIEF-EF
question-
naire
(IIEF-
EF score ≥
26) and
scheduled
to undergo
bilateral
nsRP were
included
Those men
with Glea-
son Score >
7, PSA >
20 ng/mL
and post-
Nightly
sildenafil
50 mg
Inter-
vention: 9
months
Washout:
1 month
Follow-up:
11 months
55.6 (5.9) NR NR NR
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Table 1. Baseline characteristics (Continued)
oper-
ative RT or
ADT were
excluded
Nightly in-
traurethral
alprostadil
56.8 (6.4) NR NR NR
Montorsi
2008
2004-
2007
87 centres
across Eu-
rope, the
US,
Canada,
and South
Africa
Men,
aged 18-
64 years,
in a het-
erosexual
relation-
ship, and
scheduled
to undergo
bilateral
NSRP
within
approx-
imately
1mo of
screening;
an interest
in resum-
ing sexual
activity
as soon
as possi-
ble after
surgery;
normal
preoper-
ative EF
(IIIEF
≥ 26 at
screening
without
the use of
therapy
or devices
for the
improve-
ment of
erections
Nightly
var-
denafil 10
mg (which
could be
decreased
to 5 mg
if required)
plus on-
demand
placebo
Inter-
vention: 9
months
Washout:
2 months
Follow-up:
13.5
months
57.4 NR NR NR
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Table 1. Baseline characteristics (Continued)
and no
previous
use of
therapy
or devices
for ED;
historical
total PSA
<10 ng/ml;
Gleason
tumour
score ≤ 7
on biopsy;
no tumour
perfora-
tion of the
prostate
capsule
were
included
Men
who had
residual
prostate
cancer or
require-
ment for
RT or
adjuvant
therapy;
need for
further
surgery
due to
haemor-
rhage; and
urethral
catheter
expected
to be in
place for
≥ 3 weeks
due to
anasto-
motic
fistula;
had con-
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Table 1. Baseline characteristics (Continued)
traindi-
cation of
PDE5I
were
excluded
Flexible-
dose
(starting at
10mgwith
the option
to titrate to
5 mg or 20
mg), on-
demand
vardenafil
plus
nightly
placebo
56.8 NR NR NR
Nightly
placebo,
on-
demand
placebo
57.1 NR NR NR
Montorsi
2014
2009-
2011
Multicen-
tre/Europe
& Canada
Men aged
< 68
years with
normal
EF who
underwent
nsRP for
organ-con-
fined, non-
metastatic
prostate
cancer
(Gleason
Score ≤
7, PSA
≤ 10 ng/
mL). Post-
surgical
inclusion
criteria
included
the devel-
Tadalafil
5 mg once
daily
Inter-
vention: 9
months
Washout:
6 weeks
Follow-up:
13.5
months
58.6 (5.
07)
NR NR NR
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Table 1. Baseline characteristics (Continued)
opment
of ED as
measured
by a par-
ticipant-
reported
Residual
Erection
Function
Score of ≤
3 (= “penis
is hard
enough
for pen-
etration
but not
completely
hard”)
were
included
Men
1) with
history of
ED 2) who
received
prior
PDE5I
treatments
3) who
received
neoadju-
vant RT or
a ADT or
were due
to receive
adjuvant
RT or
ADT,
4) with
history of
prostatic
surgery or
prostatic
physical
treat-
ments,
5) with
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Table 1. Baseline characteristics (Continued)
history of
diabetes
mellitus,
6) with
history of
galactose
intoler-
ance, lapp
lactase
deficiency,
or glucose-
galactose
malab-
sorption 7)
who have
clinically
significant
renal in-
sufficiency
were
excluded
Tadalafil
20 mg on-
demand
57.5 (5.
91)
NR NR NR
Placebo 57.6 (5.
69)
NR NR NR
Pace 2010 2005-
2009
Single cen-
tre/Italy
Men with
total
PSA level <
10 ng/mL,
Gleason
score ≤ 7
on biopsy,
no capsu-
lar involve-
ment, a
nor-
mal preop-
erative
EF assessed
by an IIEF
score≥ 26,
with-
out the use
of any
therapy for
improving
erection
Silde-
nafil 50mg
or 100 mg
at night for
8 weeks
Inter-
vention: 8
weeks
Washout:
14 weeks
Follow-up:
24 months
NR 5.5 (range
1.2-9.9)
6: 18 (90.
0%)
7: 2 (10.
0%)
T1b and
T1c: 10
(50.0%),
T2a: 9 (45.
0%), T2b:
1 (5.0%)
No
treatment
NR 6 (range 1.
8-8.9)
6: 18 (90.
0%)
7: 2 (10.
T1b and
T1c: 9 (45.
0%); T2a:
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Table 1. Baseline characteristics (Continued)
0%) 9 (45.0%);
T2b: 2 (10.
0%)
Padma-
Nathan
2008
1999-
2001
16 sites in
North
Amer-
ica, France,
Bel-
gium and
Australia
screened
partic-
ipants, and
11 sites in
North
America
and France
Men
aged 18-70
years,
weighing
50-125 kg
who had
to had nor-
mal preop-
erative EF
(combined
score ≥
8 on ques-
tions 3 and
4 of the
IIEF ques-
tion-
naire) and
wish to re-
turn to sex-
ual activity
af-
ter surgery
and be in a
stable, het-
ero-
sexual rela-
tionship
for the past
6 months
Sildenafil
100 mg
once
nightly
Interven-
tion: 36
weeks
Washout:
8 weeks
Follow-up:
48 weeks
55 ± 6/ NR NR NR
Silde-
nafil 50mg
once
nightly
55 ± 6 NR NR NR
Placebo
once
nightly
57 ± 7 NR NR NR
Pavlovich
2013
2006-
2007
Sin-
gle institu-
tion/USA
Men who
chose to
undergo
nsRP who
satisfied
the fol-
lowing
criteria:
aged <
65 years,
untreated
prostate
cancer
< cT2b,
biopsy
Nightly
silde-
nafil 50mg
with on-
demand
placebo
Interven-
tion: 12
months
Washout:
4 weeks
Follow-up:
13 months
54.
3 (range 2-
63)
4.7 (range
0.6-14)
6: 41 (82.
0%) 7: 9
(18.0%)
T1c: 37
(74.0%)
, T2a: 13
(26.0%)
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Table 1. Baseline characteristics (Continued)
Gleason
score < 8,
baseline
IIEF-EF
score ≥
25/30, no
PDE5I
use, and
presence
of a steady
sexual
partner
On-
demand
silde-
nafil 50mg
(maxi-
mum 6
tablets/
month)
with
nightly
placebo
53.6
(range 40-
64)
5.1 (range
0.8-9.0)
6: 42 (84.
0%)/7: 8
(16.0%)
T1c: 40
(80.0%)
; T2a: 10
(20.0%)
ADT: androgen deprivation therapy; ED: erectile dysfunction; EF: erectile function; IIEF-EF: International Index of Erectile Function
- Erectile Function domain; n: number of participants; NA: not applicable; NR: not reported; nsRP: nerve-sparing radical prostate-
ctomy; PDE5I: phosphodiesterase Inhibitor 5 inhibitor; PSA: prostate-specific antigen; RT: radiotherapy; SD: standard deviation;
SEP: Sexual Encounter Profile.
aIntervention started within 1 month after surgery in all included studies except Montorsi 2008 (14 days after surgery) and Montorsi
2014 (starting date of intervention: not defined).
Table 2. Participants disposition of included studies
Study Intervention (s)
and comparator
(s)
Screened/
eligible (n)
randomised (n) Analysed (effi-
cacy; n)a
Analysed
(safety; n)
Finishing trial
(n (%))b
Aydogdu 2011 Tadalafil 20 mg/
day, 3 days/week
85/74 NR 32 NR 32
No treatment NR 33 NR 33
Total 74 65 - 65
Kim 2016 Daily sildenafil
50 mg
100/97 49 47 47 37
On-demand
sildenafil 100mg
48 47 47 37
Total 97 94 94 74
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Table 2. Participants disposition of included studies (Continued)
McCullough
2010
Daily sildenafil
citrate 50 mg
227/212 73 59 NR 59
Daily
intraurethral al-
prostadil 125 µg
(dose titration
250 µg)
139 97 NR 97
Total 212 156 - 156
Montorsi 2008 Daily vardenafil
5-10 mg
997/628 210 143 207 137
On-demand var-
denafil 5-20 mg
208 149 204 141
Placebo 210 153 206 145
Total 628 445 617 423
Montorsi 2014 Daily tadalafil 5
mg
583/423 139 139 139 98
On-demand
tadalafil 20 mg
143 142 143 112
Placebo 141 141 141 105
Total 423 422 423 315
Pace 2010 Daily sildenafil
50mg or 100 mg
NR/40 20 20 NR 20
No treatment 20 20 NR 20
Total 40 40 - 40
Padma-Nathan
2008
Daily sildenafil
100 mg
238/125 41 28 41 28
Daily sildenafil
50 mg
41 23 40 23
Placebo 43 25 42 25
Total 125 76 123 76
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Table 2. Participants disposition of included studies (Continued)
Pavlovich 2013 Daily sildenafil
50 mg with on-
demand placebo
102/100 50 36 50 36
On-de-
mand sildenafil
50 mg (maxi-
mum 6 tablets/
month) with
daily placebo
50 38 50 38
Total 100 74 100 74
Grand Total 1699 1307 1357 1223
n: number of participants; NR: not reported.
aThe number of participants in erectile function outcome.
bThe number of participants finishing the trial at the end of the washout period or open-label treatment.
A P P E N D I C E S
Appendix 1. MEDLINE (via OvidSP)
1. Alprostadil/
2. “Prostaglandin E1”.tw
3. alprostadil.tw
4. sildenafil.tw
5. viagra.tw
6. tadalafil.tw
7. cialis.tw
8. vardenafil.tw
9. levitra.tw
10. “penile rehabilitation”.tw
11. “erect$ rehabilitation”.tw
12. “vacuum therapy”.tw
13. “vacuum erection device$”.tw
14. VED.tw
15. “vacuum constriction device$”.tw
16. VCD.tw
17. exp Phosphodiesterase 5 Inhibitors/
18. (Phosphodiesterase adj1 “5 Inhibit$”).tw
19. (Phosphodiesterase adj1 “V Inhibit$”).tw
20. (PDE5 OR PDE-5 OR “PDE 5”) adj1 inhibit$.tw
21. PDE5-I.tw
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22. Muse$.tw
23. ICI.tw
24. “intracavernosal injection$”.tw
25. OR/1-24
26. exp Erectile Dysfunction/
27. “erectile dysfunction”.tw
28. “erectile function”.tw
29. ED.tw
30. impoten$.tw
31. poten$.tw
32. ((sex or sexual$) adj3 (function$ or dysfunc$ or satisf$ or problem$ or symptom$ or arous$ or activ$ or rehabilitation OR “quality
of life”)).tw
33. OR/26-32
34. exp Prostatectomy/
35. prostatectom$.tw
36. RP.tw
37. OR/34-36
38. exp Prostatic Neoplasms/
39. “prostat$ cancer”.tw
40. “prostat$ neoplasm$”.tw
41. CaP.tw
42. OR/38-41
43. 37 AND 42
44. 25 AND 33 AND 43
Appendix 2. MEDLINE via Embase
1. prostaglandin E1/
2. “Prostaglandin E1”.tw
3. alprostadil.tw
4. sildenafil.tw
5. viagra.tw
6. tadalafil.tw
7. cialis.tw
8. vardenafil.tw
9. levitra.tw
10. “penile rehabilitation”.tw
11. “erect$ rehabilitation”.tw
12. “vacuum therapy”.tw
13. “vacuum erection device$”.tw
14. VED.tw
15. “vacuum constriction device$”.tw
16. VCD.tw
17. exp Phosphodiesterase V Inhibitors/
18. (Phosphodiesterase adj1 “5 Inhibit$”).tw
19. (Phosphodiesterase adj1 “V Inhibit$”).tw
20. ((PDE5 OR PDE-5 OR “PDE 5”) adj1 inhibit$).tw
21. PDE5-I.tw
22. Muse$.tw
23. ICI.tw
24. “intracavernosal injection$”.tw
25. OR/1-24
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26. exp Erectile Dysfunction/
27. “erectile dysfunction”.tw
28. “erectile function”.tw
29. ED.tw
30. Impotence/
31. impoten$.tw
32. poten$.tw
33. ((sex or sexual$) adj3 (function$ or dysfunc$ or satisf$ or problem$ or symptom$ or arous$ or activ$ or rehabilitation OR “quality
of life”)).tw
34. OR/26-33
35. exp Prostatectomy/
36. Prostatectom$.tw
37. RP.tw
38. OR/35-37
39. exp prostate tumor/
40. “prostat$ cancer”.tw
41. “prostat$ neoplasm$”.tw
42. CaP.tw
43. OR/39-42
44. 38 AND 43
45. 25 AND 34 AND 44
Appendix 3. The Cochrane Library via Wiley
1. MeSH descriptor: [Alprostadil] explode all trees
2. “Prostaglandin E1“:ti,ab,kw
3. alprostadil:ti,ab,kw
4. sildenafil:ti,ab,kw
5. viagra:ti,ab,kw
6. tadalafil:ti,ab,kw
7. cialis:ti,ab,kw
8. vardenafil:ti,ab,kw
9. levitra:ti,ab,kw
10. ”penile rehab*“:ti,ab,kw
11. ”erect* rehab*“:ti,ab,kw
12. ”vacuum therapy“:ti,ab,kw
13. ”vacuum erection device*“:ti,ab,kw
14. VED:ti,ab,kw
15. ”vacuum constriction device*“:ti,ab,kw
16. VCD:ti,ab,kw
17. MeSH descriptor: [Phosphodiesterase 5 Inhibitors] explode all trees
18. (Phosphodiesterase next ”5 Inhibit*“):ti,ab,kw
19. (Phosphodiesterase next ”v Inhibit*“):ti,ab,kw
20. ((PDE5 or PDE-5 or ”PDE 5“) next inhibit*):ti,ab,kw
21. (PDE5-I):ti,ab,kw
22. muse*:ti,ab,kw
23. ICI:ti,ab,kw
24. ”intracavernosal injection*“:ti,ab,kw
25. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
or #21 or #22 or #23 or #24
26. MeSH descriptor: [Erectile Dysfunction] explode all trees
27. (erect* near/3 (dysfunction or function* or capacity or failure)):ti,ab,kw
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28. ED:ti,ab,kw
29. impoten*:ti,ab,kw
30. poten*:ti,ab,kw
31. ((sex or sexual*) near/3 (function* or dysfunc* or satisf* or problem* or symptom* or arous* or activ* or rehabilitation or ”quality
of life“)):ti,ab,kw
32. #26 or #27 or #28 or #29 or #30 or #31
33. MeSH descriptor: [Prostatectomy] explode all trees
34. Prostatectom*:ti,ab,kw
35. rp:ti,ab,kw
36. #33 or #34 or #35
37. MeSH descriptor: [Prostatic Neoplasms] explode all trees
38. ”prostat* cancer“:ti,ab,kw
39. ”prostat* neoplasm*“:ti,ab,kw
40. CaP:ti,ab,kw
41. #37 or #38 or #39 or #40
42. #36 and #41
43. #25 and #32 and #42
C O N T R I B U T I O N S O F A U T H O R S
YP: drafted the protocol, undertook data collection, analysis and drafted the final review.
JHJ: undertook data collection, analysis and drafted the final review.
MS: conceptualised the review topic and drafted the protocol.
SO: developed and ran the search strategy.
CB: developed and ran the search strategy.
JB: undertook data collection,
PD: conceptualised the review topic, drafted the protocol and provided oversight.
D E C L A R A T I O N S O F I N T E R E S T
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S O U R C E S O F S U P P O R T
Internal sources
• Minneapolis VAMC and UMN Department of Urology, USA.
Protected research time
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review was based on a published protocol with differences as described below (Philippou 2016).
• We removed the comparison of on-demand PDE5 versus placebo/no treatment as on-demand dosing is not an established
method of penile rehabilitation.
• We divided time points into short-term and long-term instead of the time points outlined in the protocol of six, 12 and 24
months. Short-term time points were 12 months or less and long-term time point were greater than 12 months.
N O T E S
We have based parts of the ’Methods’ section of this protocol on a standard template developed by the Cochrane Metabolic and
Endocrine Disorders Group, which has been modified and adapted for use by Cochrane Urology.
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